pravastatin has been researched along with lovastatin in 485 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.82) | 18.7374 |
| 1990's | 260 (53.61) | 18.2507 |
| 2000's | 170 (35.05) | 29.6817 |
| 2010's | 46 (9.48) | 24.3611 |
| 2020's | 5 (1.03) | 2.80 |
| Authors | Studies |
|---|---|
| Blankley, CJ; Krause, BR; Newton, RS; Picard, JA; Roark, WH; Roth, BD; Sekerke, C; Shaw, MK; Sliskovic, DR; Stanfield, RL | 1 |
| Draper, CD; Hutson, JL; Inglis, GG; Procopiou, PA; Ross, BC; Watson, NS | 1 |
| Hsiang, B; Kirchgessner, TG; Sasseville, V; Wang, Z; Wu, Y; Yang, WP; Zhu, Y | 1 |
| Campbell, SD; Chen, C; Lin, J; Mills, JB; Mireles, RJ; Smolarek, TA; Xu, JJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Balogh, I; Kim, HY; Koczok, K; Korade, Z; Liu, W; Mirnics, K; Porter, NA; Tallman, KA; Xu, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bowornwiriyapan, K; Duangjai, A; Muanprasat, C; Phainuphong, P; Phongpaichit, S; Rukachaisirikul, V; Saithong, S; Sakayaroj, J; Srimaroeng, C | 1 |
| Block, GA; Mitchel, YB; Shapiro, DR; Tobert, JA | 1 |
| Fukami, M; Fukuda, K; Koga, T; Koike, H; Shimada, Y; Tsujita, Y | 1 |
| Cohen, L; Crommelin, D; Geelhoed-Mieras, T; Griffioen, M; Joles, J; Koomans, H; Krajnc-Franken, M; Van Bloois, L; Van Tol, A; Willekes-Koolschijn, N | 1 |
| Alessandri, C; Peverini, F | 2 |
| Toyota, T | 1 |
| Corsini, A; Gabbiani, G; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Jacob, BG; Möhrle, W; Richter, WO; Schwandt, P | 1 |
| Behrens-Baumann, W; Thiery, J | 1 |
| Amin, RD; Brunner-Ferber, F; Pentikainen, PJ; Rogers, JD; Saraheimo, M; Schwartz, JI; Schwartz, MS | 1 |
| Lee, RM; Merlotti, L; Richardson, GR; Roehrs, T; Roth, T; Sullivan, JP | 1 |
| Miettinen, TA; Vanhanen, H | 1 |
| Spielberg, SP; Tobert, JA | 1 |
| Eda, T; Hidaka, Y; Kamei, T; Yonemoto, M | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ | 1 |
| Kostis, JB; Wilson, AC | 1 |
| Illingworth, DR | 1 |
| Bak Mueller, S; Bocan, TM; Dehart, P; Ferguson, E; Krause, BR; McNally, W; Newton, RS; Roth, BD; Sliskovic, DR; Uhlendorf, PD | 1 |
| Bixler, EO; Kales, A; Manfredi, RL; Tyson, KL; Vgontzas, AN | 1 |
| Hockwin, O; Schmidt, J; Schmitt, C | 1 |
| Mahoney, EM; Ranadive, SA; Serajuddin, AT | 1 |
| Collins, P; Johnson, A; Owens, D; Robinson, K; Tighe, O; Tomkin, GH | 1 |
| Miettinen, TA | 1 |
| Ditschuneit, H; Ditschuneit, HH; Kuhn, K | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; Kari, PH; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ; Vyas, KP | 1 |
| Matsuoka, T; Serizawa, N | 1 |
| Corsini, A; Fumagalli, R; Paoletti, R; Raiteri, M; Soma, M | 1 |
| Botti, RE; Pan, HY; Triscari, J; Zayat, J | 1 |
| DeVault, AR; Pan, HY; Smith, SA; Swanson, BN; Triscari, J; Wang-Iverson, D; Willard, DA | 1 |
| Kalinowski, SS; Mosley, ST; Tanaka, RD | 1 |
| Jacob, BG; Richter, WO; Schwandt, P | 3 |
| Endo, A | 1 |
| Bain, SC; Jones, AF; Lemon, M; Walker, MR | 1 |
| Grundy, SM; Krauss, RM; Vega, GL | 1 |
| Ishida, F; Kakubari, K; Kamei, T; Kitani, K; Sato, A; Taguchi, K; Watanabe, K | 1 |
| Aronson, JK; Ng, LL | 1 |
| Maher, VM; Thompson, GR | 1 |
| Bocanegra, TS; Tobert, JA | 1 |
| Hasegawa, K; Koga, T; Kuroda, M; Shimada, Y; Tsujita, Y; Yamazaki, M | 1 |
| Matsuoka, T; Nakahara, K; Serizawa, N | 1 |
| DeVault, AR; Ivashkiv, E; Pan, HY; Sugerman, AA; Swanson, BN; Wang-Iverson, D | 1 |
| Hayaishi, O; Islam, F; Watanabe, Y | 1 |
| Freudenberger, JS; Lee, LY; Mosley, ST; Schafer, BL; Tanaka, RD | 1 |
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
| Alberts, AW; Bailey, PJ; Bostedor, RG; Germershausen, JI; Hunt, VM; Karkas, JD | 1 |
| Hosobuchi, M; Matsuoka, T; Miyakoshi, S; Nakahara, K; Serizawa, N; Tanzawa, K | 1 |
| Kalinowski, SS; Mosley, ST; Schafer, BL; Tanaka, RD | 1 |
| Tobert, JA | 4 |
| Oliver, MF | 2 |
| Kikuchi, T; Koga, T; Koike, H; Miyazaki, A | 1 |
| Abiko, Y; Ichihara, K; Satoh, K | 1 |
| Smart, AJ; Walters, L | 1 |
| Tonkin, AM | 1 |
| Gotto, AM; Jones, PH | 1 |
| Simes, RJ | 1 |
| Branchi, A; Fiorenza, AM; Rovellini, A; Sommariva, D | 1 |
| Garnett, WR | 2 |
| Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Block, G; Cutler, N; Lines, C; Sramek, J; Stauffer, L; Veroff, A | 1 |
| Amigues, O; Bour Guichenez, G; Cambazard, F; Guy, C; Perrot, JL; Servoz, J | 1 |
| Levenstein, S | 1 |
| Agner, E; Agner, T; Malinowski, J; Meibom, J; Ramsing, D | 1 |
| Borysiuk, L; Korman, L | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Jorge, PA; Metze, K; Ozaki, MR | 1 |
| MacDonald, JS | 1 |
| Pedreño, J; Ros, E; Sánchez, JL; Zambón, D | 1 |
| Shepherd, J | 1 |
| Bär, PR; Contermans, J; Erkelens, DW; Smit, JW | 1 |
| Baker, JR; Fosso, CK; Miller, MJ; Solomon, WR | 1 |
| Bertolami, MC; Diament, J; Faludi, AA; Forti, N; Giannini, SD; Schölz, J | 1 |
| Block, G; Cwudzinski, D; Gengo, F; Kinkel, P; Lines, C; Stauffer, L | 1 |
| Ichihara, K; Satoh, K | 1 |
| Ichihara, K; Nakai, T; Satoh, K | 1 |
| Kostis, JB; Rosen, RC; Wilson, AC | 1 |
| Carmena, R | 1 |
| Durham, SK; Flint, OP; Gregg, RE; Masters, BA; Palmoski, MJ; Wang-Iverson, D | 1 |
| Faccini, G; Moghetti, P; Muggeo, M; Negri, C; Tosi, F; Travia, D | 1 |
| Erkelens, DW; Illingworth, DR; Keller, U; Thompson, GR; Tikkanen, MJ | 1 |
| Rosenson, RS; Stein, JH | 1 |
| Cremer, P; Seidel, D | 1 |
| Fukaura, Y; Ishikawa, C; Narisawa, T; Tanida, N; Terada, K; Umezawa, A; Yazawa, K | 1 |
| Panuccio, D; Romani, A; Trabatti, MR | 1 |
| Campana, C; Gavazzi, A; Iacona, I; Perani, G; Regazzi, MB; Viganò, M | 1 |
| Cummings, MH; Watts, GF | 1 |
| Steinhagen-Thiessen, E | 1 |
| Gørbitz, C; Malt, UF; Ose, L; Tonstad, S | 1 |
| Miettinen, TA; Partinen, M; Pihl, S; Räikkönen, K; Strandberg, TE; Vanhanen, H | 1 |
| Arimura, K; Gotow, T; Kuriyama, M; Nakahara, K; Osame, M; Sonoda, Y | 1 |
| Kuriyama, M; Nakahara, K; Osame, M; Yada, T | 1 |
| al-Shurbaji, A; Berglund, L; Humble, E; Lund, E | 1 |
| Sirtori, CR | 1 |
| Carlsen, SM; Fougner, KJ | 1 |
| Ma, L; Morita, I; Murota, S | 1 |
| Goldstein, MR | 2 |
| Korman, LB | 1 |
| Lambrecht, LJ; Malini, PL | 1 |
| Emmerich, J | 1 |
| Jacobs, MB | 1 |
| Farbstein, S | 1 |
| Block, G; Haigh, J; Miettinen, T; Murtomäki, E; Neafus, R; Partinen, M; Pihl, S; Reines, S; Strandberg, T; Vanhanen, H | 1 |
| Ashton, CH; Harrison, RW | 1 |
| Corsini, A; Fumagalli, R; Gabbiani, G; Mazzotti, M; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Bremer, J; Lintott, CJ; Scott, RS; Sutherland, WH | 1 |
| Bailey, EJ; Chan, C; Hartley, CD; Hayman, DF; Hutson, JL; Inglis, GG; Jones, PS; Keeling, SE; Kirk, BE; Lamont, RB | 1 |
| Mazzanti, L; Polenta, M; Rabini, RA; Signore, R; Staffolani, R; Testa, I; Tocchini, M | 1 |
| Saheki, A; Tamai, I; Terasaki, T; Tsuji, A | 1 |
| Fukami, M; Fukushige, J; Kogure, Y; Maeda, N; Ogawa, T; Shimada, Y; Tsujita, Y | 1 |
| De Haan, AF; Kastelein, JJ; Kortmann, B; Kroon, AA; Lansberg, PJ; Stalenhoef, AF; Stuyt, PM | 1 |
| De Haan, AF; Demacker, PN; Kleinveld, HA; Stalenhoef, AF | 1 |
| Holdcroft, C | 1 |
| Golay, A; James, R; Lehmann, T; Pometta, D | 1 |
| Kerry, NL; Nestel, PJ; Roach, PD; Whiting, MJ | 1 |
| Bayne, WF; Gilbert, JD; Hsieh, JY; Matuszewski, BK; Morris, MJ; Ramjit, HG | 1 |
| Amin, D; Cornell, SA; Gustafson, SK; Kosmider, B; Neuenschwander, K; Perrone, MH; Regan, JR; Scotese, AC; Weinacht, JM | 1 |
| Bloemendal, H; Cohen, LH; de Vries, AC; Vermeer, MA | 1 |
| Cohen, LH; de Vries, AC | 1 |
| Caputo, S; Ghirlanda, G; Greco, AV; Lippa, S; Littarru, GP; Manto, A; Oradei, A; Uccioli, L | 1 |
| Donetti, E; Ferrari, C; Fumagalli, R; Mazzini, G; Paoletti, R; Parolini, C; Soma, MR | 1 |
| Block, GA; Eckernäs, SA; Eriksson, LO; Haigh, JR; Kvidal, P; Neafus, RP; Roos, BE | 1 |
| Stricker, BH; Wolterbeek, R | 1 |
| Bär, PR; Bredman, JJ; Cohen, LH; De Vries, AC; Vermeer, MA | 1 |
| Burg, G; Elsner, P; Krasovec, M | 1 |
| Cohen, LH; Griffioen, M; Jansen, LM; Roodenburg, L; van Vliet, A | 1 |
| Hoshi, K; Ichihara, K; Nakai, T; Satoh, K; Yamato, A | 1 |
| Camerino, DC; De Luca, A; Ferrannini, E; Laico, M; Natuzzi, F; Pierno, S; Roselli, A; Tricarico, D | 1 |
| Martínez-Castelao, A | 1 |
| Boyd, I; England, JD; Halmagyi, GM; Rohan, A; Stewart, P; Walsh, JC | 1 |
| Gotto, AM; Hay, JW | 1 |
| Lopez, D; Ness, GC; Zhao, Z | 1 |
| Arnaboldi, L; Corsini, A; Fumagalli, R; Paoletti, R; Quarato, P; Raiteri, M | 1 |
| Del Puppo, M; Galli Kienle, M; Rauli, S | 1 |
| Dobs, AS; Goldberg, A; Guccione, M; Hoover, DR; Prasad, M | 1 |
| Caruso, AP; Gadbut, AP; Galper, JB | 1 |
| Cooper, ME; Gilbert, RE; Jerums, G | 1 |
| Benders, AA; Oosterhof, A; Smit, JW; Veerkamp, JH | 1 |
| Berger, ML; Liss, CL; Santanello, NC; Weeks, ML; Weir, MR | 1 |
| Holme, I | 1 |
| Cohen, LH; Naaktgeboren, N; van Thiel, GC; van Vliet, AK | 1 |
| Olsson, AG | 1 |
| Feingold, KR; Marcelino, JJ | 1 |
| Thompson, GR | 1 |
| Pedersen, TR; Tobert, JA | 1 |
| Drown, DJ | 1 |
| Kimura, T; Komai, T; Masuda, H; Nomoto, K; Shinkai, K | 1 |
| Bär, PR; Bredman, JJ; Joles, JA; Koot, RW; Reijneveld, JC | 1 |
| Berardesca, E; Brazzelli, V; Distante, F; Perani, G | 1 |
| Dayer, P; Leemann, T; Transon, C | 1 |
| Simons, LA | 1 |
| Hosomi, N; Izumi, Y; Kitadai, M; Satoh, K; Takahashi, T; Tsuda, Y | 1 |
| Colette, C; Crastes De Paulet, A; Descomps, B; Farnier, M; Feillet, C; Monnier, LH; Percheron, C | 1 |
| Campagnoli, G; Dorigotti, F; Franceschini, G; Gianfranceschi, G; Pazzucconi, F; Sirtori, CR; Sirtori, M | 1 |
| Clem, JR | 1 |
| Ballantyne, CM; Bourge, RC; Domalik, LJ; Eisen, HJ; Fishbein, DP; Kubo, SH; Lake, KD; Radovancevic, B; Taylor, DO; Ventura, HO; Yancy, CW; Young, JB | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Northridge, D; Wright, R | 1 |
| Hughes, AD | 1 |
| Buckley, BM; Murphy, MB; Vaughan, CJ | 1 |
| Rackley, CE | 1 |
| Kada, M; Komai, T; Kurakata, S; Nomoto, K; Shimada, Y | 1 |
| Dotti, MT; Federico, A; Lindenthal, B; Lütjohann, D; Simatupang, A; von Bergmann, K | 1 |
| Donetti, E; Fumagalli, R; Paoletti, R; Parolini, C; Soma, MR | 1 |
| Pederson, JP; Weintraub, WS | 1 |
| Masters, P; Shetty, A | 1 |
| Wanner, C | 1 |
| Bolhuis, PA; Cohen, LH; Nègre-Aminou, P; van Thiel, GC; van Vliet, AK | 1 |
| Marchioli, R; Tognoni, G | 1 |
| Ganotatis, ES; Jagroop, IA; Mikhailidis, DP; Winder, AF | 1 |
| Rosenson, RS; Tangney, CC | 2 |
| Badimon, L; Martínez-González, J | 1 |
| Komatsu, N; Kunitama, M; Miura, Y | 1 |
| Boddaert, M; Christians, U; Doll, R; Eisenhauer, T; Kliem, V; Krekler, M; Mangold, B; O'Grady, P; Olbricht, CJ; Wanner, C | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Murota, S; Sato-Suzuki, I | 1 |
| Jackson, PR; Payne, JN; Pickin, DM; Ramsay, LE; Ul Haq, I; Yeo, WW | 1 |
| Ichikawa, M; Matsuyama, K; Nakai, A; Nishikata, M; Uchida, T | 1 |
| Angelin, B; Juliusson, G; Vitols, S | 1 |
| Catovsky, D; Clutterbuck, RD; Millar, JL; Newman, A; Powles, RL | 1 |
| Desager, JP; Horsmans, Y | 1 |
| Dal Piaz, A; De Venuto, G; Focher, C; Miori, R; Ramponi, C; Spagnolli, W; Torboli, P | 1 |
| Ganotakis, ES; Mikhailidis, DP; Winder, AF | 1 |
| Applegate, WB; Cushman, W; Elam, MB; Heimberg, M | 1 |
| Cohen, LH; Nègre-Aminou, P; van Erck, M; van Leeuwen, RE; van Thiel, GC; van Vliet, AK | 1 |
| Fager, G; Lennernäs, H | 1 |
| Byington, RP; Crouse, JR; Furberg, CD; Hoen, HM | 1 |
| Roberts, WC | 1 |
| Bhatnagar, D | 1 |
| Durham, SK; Flint, OP; Gregg, RE; Masters, BA | 2 |
| Durrington, P | 1 |
| Biwa, T; Hakamata, H; Horiuchi, S; Kobori, S; Matsumura, T; Sakai, M; Sato, Y; Shichiri, M; Takemura, T | 1 |
| Agner, E; Leth, A; Mortensen, SA; Rohde, M | 1 |
| Itoh, H; Kuriyama, K; Nakagawa, M; Nakata, T; Sasaki, S; Sawada, S; Takeda, K | 1 |
| Scheen, AJ | 1 |
| Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA | 1 |
| Aoki, T; Kimata, H; Kitahara, M; Kojima, J; Nakagawa, S; Nishimura, H; Saito, Y; Sakashita, M; Sato, F; Suzuki, H; Tamaki, T; Toyoda, K; Wada, Y; Yokoo, N | 1 |
| Boddaert, M; Christians, U; Doll, R; Eisenhauer, T; Kliem, V; Krekler, M; Mangold, B; O'Grady, P; Olbricht, C; Wanner, C | 1 |
| Markowitz, JS; McGovern, MW; Triscari, J | 1 |
| Verheugt, FW | 1 |
| Demain, AL; Peng, Y; Yashphe, J | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| Serizawa, N; Watanabe, I | 1 |
| Grundy, SM | 1 |
| Chan, KW; Kao, SM; Yang, YH | 1 |
| Evans, MF; Por, CP; Sabharwal, M | 1 |
| Pearson, TA | 1 |
| Mabuchi, H | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Pincus, J | 1 |
| Anand, R; Burrows, L; Genyk, Y; Knight, R; Moran, V; Schwartz, B | 1 |
| Davignon, J; Hanefeld, M; Hunninghake, DB; Insull, W; Nakaya, N; Ose, L | 1 |
| Eriksson, M | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Sinzinger, H | 2 |
| Otto, C; Schwandt, P | 1 |
| Azie, NE; Becker, PA; Brater, DC; Hall, SD; Jones, DR | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Echeandia, C; Figuerola, A; Marta-Moreno, J; Mola, S; Oliveros-Cid, A | 1 |
| Benet, LZ; Christians, U; Deters, M; Hackbarth, I; Hallensleben, K; Jacobsen, W; Kirchner, G; Mancinelli, L; Sewing, KF | 1 |
| Corbett, KE; Dallal, GE; Ehrenberg, BL; Lamon-Fava, S; McNamara, JR; Schaefer, EJ | 1 |
| Gaziano, JM; Lapsley, D; Strauss, WE | 1 |
| Dyer, Z; Gelberg, HJ; Kupperman, JL; Liebhaber, MI; Wright, RS | 1 |
| Bottorff, MB; Cave, DG; Yenkowsky, JP | 1 |
| Bush, AC; Carr-Lopez, S; Exstrum, T; Morse, T; Shepherd, M | 1 |
| O'Grady, J; Schmid, P; Sinzinger, H | 1 |
| Nicholson, CR | 1 |
| Coelho, OR; Mansur, AP; Nicolau, JC; Ramires, JA; Spósito, AC | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Gray, DR; Jafari, M; Patel, RJ; Pierce, R | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Blanco-Colio, LM; Egido, J; Guijarro, C; Kasiske, BL; Keane, WF; Massy, ZA; O'Donnell, MP | 1 |
| Haneda, T; Kashiwagi, Y; Kawabe, J; Kikuchi, K; Nakamura, Y; Oi, S; Osaki, J | 1 |
| Asenjo-Barrón, JC; Cárdenas-Vázquez, R; Díaz-Zagoya, JC; Juárez-Oropeza, MA; Martínez, F | 1 |
| Gotto, AM | 3 |
| Baner, K; Benet, LZ; Christians, U; Deters, M; Hackbarth, I; Hallensleben, K; Jacobsen, W; Kirchner, G; Mancinelli, L; Sewing, KF | 1 |
| Axel, DI; Fenchel, M; Herzog, UU; Karsch, KR; Riessen, R; Rossmann, H | 1 |
| Menotti, A; Poli, A | 1 |
| Farnier, M | 1 |
| Delanty, N; Mohler, ER; Rader, DJ; Raps, EC | 1 |
| Bakker-Arkema, RG; Black, DM; Nawrocki, JW | 1 |
| Stalenhoef, AF; Stehouwer, CD | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Rosenson, RS | 2 |
| Abe, K; Asami, S; Kodama, T; Konishi, K; Oikawa, S; Sugiyama, M | 1 |
| Breithardt, G; Fan, L; March, KL; Müller, JG; Schmidt, A; Sindermann, JR; Troyer, D; Weigel, KA | 1 |
| Smith, SC | 1 |
| Honda, H; Kobayashi, T | 1 |
| Cobos, A; García-Altés, A; García-Closas, R; Jovell, AJ; Serra-Majem, L | 1 |
| Albani, D; Bruno, A; Diomede, L; Fruscella, P; Guglielmotti, A; Mantovani, A; Massimiliano, L; Pinza, M; Polentarutti, N; Romano, M; Salmona, M; Sironi, M; Sottocorno, M; Vecchi, A | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| Verdery, R | 1 |
| Fruchart, JC | 1 |
| Ikeda, U; Inaba, H; Ohki, R; Shimada, K; Shimpo, M; Takahashi, M; Yamamoto, K | 1 |
| Celesia, GG; Kellman, W; Ruosseau, P; Siegel, G; Wolozin, B | 1 |
| Browner, WS; Grady, D; Hulley, SB | 1 |
| Matsuda, T; Muraki, Y; Nagasawa, K; Ohnishi, N; Yokoyama, T | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Naito, A | 1 |
| Kwak, B; Mach, F; Mulhaupt, F; Myit, S | 1 |
| García-Altés, A; Jovell, AJ | 1 |
| Davidson, MH | 1 |
| Stein, EA | 2 |
| Feinberg, AW | 1 |
| Cheng, JW; Sotiriou, CG | 1 |
| Gross, W; März, W; Müller, HM; Olbrich, HG; Siekmeier, R; Wieland, H | 1 |
| Alvarez, AM; García-Román, N; Lorenzo, MJ; Montes, A; Toro, MJ | 1 |
| Kersting, F; Selenka, A; Walch, S | 1 |
| Moulin, P | 1 |
| Crouch, MA | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Dzien, A; Dzien-Bischinger, C; Hoppichler, F; Lechleitner, M | 1 |
| Wierzbicki, AS | 1 |
| Waters, DD | 1 |
| Brinkmann, V; Bruns, C; Cottens, S; Hommel, U; Kallen, J; Kamata, T; Takada, Y; Weitz-Schmidt, G; Welzenbach, K | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Bollen, EL; Buckley, BM; Gaw, A | 1 |
| Bastarda, A; Grahek, R; Kracun, M; Milivojevic, D | 1 |
| Golomb, BA; Jaworski, B | 1 |
| Walczak, IM | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Eberlein, M; Goppelt-Struebe, M; Heusinger-Ribeiro, J | 1 |
| Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH | 1 |
| Le, NA | 1 |
| Bower, EA; Gibellato, MG; Moore, JL; Selby, K | 1 |
| Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Auer, J; Eber, B | 1 |
| Bottorff, M; Worz, CR | 1 |
| Alton, KB; Burrier, RE; Davis, HR; Pula, KK; Watkins, RW | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bazalo, GR | 1 |
| Werkö, L | 1 |
| Chen, H; Liu, R; Xing, Y | 1 |
| Cole, WC; Kumar, B; Prasad, KN | 1 |
| Fujita, T; Izumo, N; Koida, M; Nakamuta, H | 1 |
| Frenette, PS | 1 |
| Iwaki, K; Kakumoto, M; Nakamura, T; Ohmoto, N; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y | 1 |
| Böhm, M; Hamm, CW; Heeschen, C; Laufs, U; Snapinn, S; White, HD | 1 |
| Andersen, M; Gaist, D; García Rodríguez, LA; Hallas, J; Jeppesen, U; Sindrup, SH | 1 |
| Altieri, PI; Crespo, MJ; Escobales, N; Furilla, RA | 1 |
| Mach, F | 2 |
| Ikeda, U; Ito, T; Ohki, R; Shimada, K; Shimpo, M; Takahashi, M; Yamamoto, K | 1 |
| Andreatta, C; Cole, WC; Edwards-Prasad, J; Koustas, WT; Kumar, B; Prasad, KN | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Granberry, MC; Kennedy, RH; Liu, H; Melchert, RB | 1 |
| Irons, BK; MacLaughlin, EJ; McCall, K; Snella, KA; Villarreal, M | 1 |
| Ahn, C; Aronow, WS | 1 |
| Mehta, JL; Singh, BK | 1 |
| Chmielewski, M; Rutkowski, B; Zdrojewski, Z | 1 |
| Feyen, JH; French, MH; Frith, JC; Güngör, T; Harrity, TW; Rogers, MJ; Staal, A; Swartz, J; Tamasi, J | 1 |
| Holme, I; Tonstad, S | 1 |
| Ferrières, J | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| McBurney, CR; Smith, DG | 1 |
| Clark, LT | 1 |
| Lipton, AM; Lutjohann, D; Moore, C; Svetlik, D; Vega, GL; Von Bergmann, K; Weiner, MF | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Baskin, F; Fang, X; Hynan, LS; Moore, CB; Rosenberg, RN; Vega, GL; Weiner, M | 1 |
| Arvik, BM; Doraiswamy, PM; Mitton, MW; Wagstaff, LR | 1 |
| Bank, I; Chess, L; Goldstein, I; Koltakov, A; Li, J; Nir-Glickman, E; Roitelman, J | 1 |
| Bergdahl, A; Hellstrand, P; Persson, E; Swärd, K | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Mishra, TK; Routray, S | 1 |
| Darvesh, S; Martin, E; Rockwood, K; Walsh, R | 1 |
| Kang, SM; Kim, YJ; Kwon, TJ; Lee, JK; Moon, SH; Park, JW; Park, YI; Suh, HH; Yi, DH | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Edwards, JE; Moore, RA | 1 |
| Fang, CH; Li, JJ | 1 |
| Tellier, P | 1 |
| Baurand, A; Bergmann, MW; Dietz, R; El Jamali, A; Freund, C; Rechner, C | 1 |
| Eckert, GP; Fechner, T; Franke, C; Igbavboa, U; Johnson-Anuna, LN; Karas, M; Keller, JH; Müller, WE; Schubert-Zsilavecz, M; Wood, WG | 1 |
| Chen, TH; Chen, WM; Chou, SH; Ko, YC; Kuo, TK; Lee, OK; Li, HJ; Su, Y | 1 |
| Chauhan, NB; Feinstein, DL; Siegel, GJ | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Dellavalle, RP; Gendall, J; Kelly, D; Miller, L; Norris, DA; Ribble, D; Shellman, YG; Vanbuskirk, K | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Bastemir, M; Emral, R; Gullu, S; Lazarus, JH; Parkes, AB | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H; Straussberg, R | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Davidson, M | 1 |
| Cannon, CP; Ray, KK | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Izar, MC | 1 |
| Crespo, MJ; Quidgley, JA | 1 |
| Brophy, JM; Costa, V | 1 |
| Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Plans-Rubió, P | 1 |
| Chen, CH; Cho, YC; Hsu, WH; Hu, HY | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Abbas, T; Dutta, A; Sivaprasad, U | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Batt, AM; Bertrand-Thiebault, C; Masson, C; Siest, G; Visvikis-Siest, S | 1 |
| Chen, C; Lin, J; Smolarek, T; Tremaine, L | 1 |
| Angri, V; Calabrò, P; Chiariello, M; Cirillo, P; De Rosa, S; Fiorentino, I; Gargiulo, A; Musto D'Amore, S; Pacileo, M; Petrillo, G; Prevete, N; Sasso, L; Ucci, G | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H | 2 |
| Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV | 1 |
| Coleman, CI; Dale, KM; Henyan, NN; Kluger, J; White, CM | 1 |
| Sylvester, PW; Wali, VB | 1 |
| George, J; Keren, G; Luboshits, G; Mausner-Fainberg, K; Maysel-Auslender, S; Mor, A; Rubinstein, A | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA | 1 |
| Brophy, MT; Farwell, WR; Fiore, LD; Gaziano, JM; Lawler, EV; Lew, RA; Scranton, RE | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Pickering, TG | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Beales, IL; Ogunwobi, OO | 1 |
| Hawk, ET; Viner, JL | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Avisar, I; Brook, JG; Wolfovitz, E | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Xiao, H; Yang, CS | 1 |
| Backman, JT; Neuvonen, PJ; Niemi, M | 1 |
| Botelho-Nevers, E; Espinosa, L; Raoult, D; Rolain, JM | 2 |
| Ford, JS; Tayek, JA | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Hanson, M; Hoffman, R; Strony, J; Veltri, E | 1 |
| Abel, T; Fehér, J | 1 |
| Bhagavan, NV; Ha, CE; Ha, JS; Theriault, AG | 1 |
| Fujii, T; Fujii, Y; Ito, M; Machida, K; Ochiai, A | 1 |
| Brañes, J; Carvajal, J; Chen-Lin, K; Cuello, M; Gejman, R; Kato, S; Oliva, B; Owen, GI; Sadarangani, A; Smalley, S | 1 |
| Fitzgerald, K; Kashanin, D; O'Dowd, F; Robinson, AJ; Walsh, GM; Williams, V | 1 |
| Backman, JT; Keskitalo, JE; Kurkinen, KJ; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Barrios-González, J; Miranda, RU | 1 |
| Chang, LC; Chen, JS; Hwang, JC; Lin, YF; Shui, HA | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Arisawa, A; Aritoku, Y; Fujii, T; Fujii, Y; Johdo, O; Kagawa, Y; Norihisa, K; Sallam, KI; Tamura, T | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Shi, J; Xue, Z | 1 |
| Lin, CL; Lin, SM; Tang, YL | 1 |
| Eberlein, B; Gebhardt, E; Gilbertz, KP; Placzek, M; Przybilla, B | 1 |
| Hong, SJ; Kim, PS; Ko, JH; Mustoe, TA; Zhao, Y | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| de Oliveira, RB; Oliveira, MA; Silva, TD; Vianna-Soares, CD | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Ba, L; Duan, Y; Li, P; Lin, Z; Zhang, H | 1 |
| Baumgarten, G; Frede, S; Hilbert, T; Hoeft, A; Klaschik, S; Knuefermann, P; Poth, J | 1 |
| Atehortúa, L; Chegwin-Angarita, C; Diaz, GJ; Jeannette Nieto-Ramirez, I; Rojas L, JR; Sepúlveda, L | 1 |
| Duleba, AJ; Ortega, I; Sokalska, A; Stanley, SD; Villanueva, JA | 1 |
| Baba, A; Kazama, I; Maruyama, Y | 1 |
| Albers, M; Baumeister, SE; Kroemer, HK; Meyer zu Schwabedissen, HE; Nauck, M; Rimmbach, C; Siegmund, W; Völzke, H; Wallaschofski, H | 1 |
| Alarcon, VB; Marikawa, Y | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Corkum, A; Fisher, J; Minard, LV; Saleh, A; Sketris, I; Zhang, Y | 1 |
| Bai, Y; Chan, C; Chang, X; Cheng, N; Cheng, Z; Lu, Y; Zhao, Y | 1 |
| Abdulmughni, A; Bernhardt, R; Hartz, P; Kern, F; Milhim, M; Putkaradze, N | 1 |
| Añino Alba, A; Fernandez-Esteban, I; Fernandez-Tabera, JM; Gómez Álvarez, P; Izquierdo-Palomares, JM; Martin-Carrillo, P; Pinar López, Ó; Plana, MN; Saiz, LC | 1 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Hayashi, K; Ikushiro, S; Kamakura, M; Ohta, M; Sakaki, T; Shiro, Y; Sugimoto, H; Takita, T; Yasuda, K; Yasukawa, K | 1 |
| Lopez, D; Melendez, QM; Wooten, CJ | 1 |
| Cook, RL; Dave, CV; Hartzema, AG; Park, H; Winterstein, AG | 1 |
| Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Krychtiuk, KA; Lenz, M; Pentz, R; Stojkovic, S; Thaler, B; Wojta, J; Zuckermann, A | 1 |
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Duleba, AJ; Hawkins, AB; Sokalska, A; Yamaguchi, T | 1 |
| Aganov, A; Galiullina, LF; Huster, D; Klochkov, V; Scheidt, HA | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Au, A; Basu, S; Collier, VJ; Hopkin, G; Naci, H; Yudkin, JS | 1 |
| da Silva, LCN; de Barros Gomes, E; de Miranda, RCM; Dias, LRL; Neto, RNM; Weba-Soares, L | 1 |
| Caspar, AT; Hemmer, S; Meyer, MR; Wagmann, L | 1 |
| de Fijter, JW; Dekker, FW; Dekkers, OM; Esmeijer, K; Hoogeveen, EK | 1 |
| Attalah Nee Rezkallah, C; Chen, QM; Thongkum, A; Zhu, C | 1 |
| Aksoy, HN; Ceylan, C | 1 |
| Chhonker, Y; Haney, SL; Holstein, SA; Murry, DJ; Smith, LM; Talmon, G; Varney, ML | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
86 review(s) available for pravastatin and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Clinical evaluation of a selective inhibitor of cholesterol synthesis: pravastatin].
Topics: Adult; Animals; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Guinea Pigs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Pravastatin; Rats; Risk Factors; Simvastatin; Time Factors | 1992 |
Clinical implications of new drugs for lowering plasma cholesterol concentrations.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1991 |
[Hypercholesterolemia: therapeutic approach].
Topics: Adult; Aged; Anticholesteremic Agents; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin | 1991 |
HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Extending the benefit of lipid-regulating therapy to primary prevention.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic | 1995 |
Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1995 |
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Topics: Anticholesteremic Agents; Biological Availability; Comorbidity; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1995 |
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.
Topics: Clinical Trials as Topic; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Topics: Anticholesteremic Agents; Cardiovascular System; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipoproteins; Lovastatin; Pravastatin; Simvastatin | 1995 |
Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rhabdomyolysis; Risk Factors; Simvastatin; Species Specificity; Structure-Activity Relationship; Tissue Distribution | 1993 |
[Side effects of cholesterol synthesis inhibitors].
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Middle Aged; Pravastatin; Rhabdomyolysis; Simvastatin | 1993 |
[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Lovastatin; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Topics: Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of lipids. Implications for the general practitioner.
Topics: Family Practice; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.
Topics: Anticholesteremic Agents; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Postoperative Complications; Pravastatin; Registries; Simvastatin; Treatment Outcome | 1996 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Pravastatin | 1996 |
The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
Topics: Animals; Anticholesteremic Agents; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Simvastatin | 1996 |
Statins do more than just lower cholesterol.
Topics: Anticholesteremic Agents; Arteries; Arteriosclerosis; Blood; Cholesterol; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Topics: Carotid Artery Diseases; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Topics: Aged; Cholesterol; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Male; Pravastatin; Pregnancy; Simvastatin | 1996 |
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Topics: Anticholesteremic Agents; Arteriosclerosis; Brain; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Food-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver; Lovastatin; Pravastatin; Simvastatin | 1997 |
Reductase inhibitor monotherapy and stroke prevention.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1997 |
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as Topic; Coronary Disease; Drug Therapy, Combination; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Triglycerides; Weight Loss | 1998 |
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Topics: Animals; Antithrombins; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Endothelium, Vascular; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lovastatin; Muscle, Smooth, Vascular; Platelet Aggregation; Pravastatin; Simvastatin; Thromboplastin; Thrombosis | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Prevention. Who should take cholesterol-lowering drugs?
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Estrogen Replacement Therapy; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Pravastatin | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Statins have other beneficial properties besides their cholesterol lowering effect].
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Coagulation; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Lovastatin; Pravastatin; Simvastatin | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
[Are there differences in various statins?].
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Topics: Adult; Arteriosclerosis; Cerebrovascular Disorders; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world].
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol; Coronary Artery Bypass; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Smoking; Time Factors | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Statins and cerebrovascular disease: plaque attack to prevent brain attack.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Vessels; Clinical Trials as Topic; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Pravastatin; Stroke | 1999 |
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome | 2000 |
[Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 2000 |
Biological basis for statin therapy in stroke prevention.
Topics: Animals; Humans; Lovastatin; Pravastatin; Simvastatin; Stroke | 2000 |
Bridging the treatment gap.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Self Medication; Simvastatin; United States | 2000 |
Fuzzy control of bioprocess in Japan.
Topics: Alcoholic Beverages; Automation; Biotechnology; Fuzzy Logic; Japan; Lovastatin; Models, Theoretical; Pravastatin; Protein Precursors; Quality Control; Temperature | 2000 |
[Tracing the past half century of my microbial transformation studies].
Topics: History, 20th Century; Lovastatin; Microbiology; Pravastatin; Prednisolone; Streptomyces; Transformation, Bacterial; Xanthenes | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.
Topics: Blood Coagulation; Blood Platelets; Blood Pressure; Blood Viscosity; Cholesterol; Coronary Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth; Pravastatin; Simvastatin | 2000 |
[Statins and cardiovascular disease prevention: use and prospective].
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin | 2000 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
What do the statin trials tell us?
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Outcome Assessment, Health Care; Pravastatin; Stroke; United States | 2001 |
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Gemfibrozil; Humans; Lovastatin; Myocardial Ischemia; Pravastatin; Risk Factors; Simvastatin; Smoking | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.
Topics: Aged; Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Drug Interactions; Enzyme Inhibitors; Female; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Isoenzymes; Itraconazole; Lovastatin; Male; Middle Aged; Muscular Diseases; Pravastatin; Rhabdomyolysis; Simvastatin | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Locking a leukocyte integrin with statins.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Lovastatin; Lymphocyte Function-Associated Antigen-1; Naphthalenes; Pravastatin; Protein Binding; T-Lymphocytes | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Update on the management of dyslipidemia.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Assessment; Risk Factors | 2002 |
Management of dyslipidemia in the primary prevention of coronary heart disease.
Topics: Animals; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2002 |
Benefits and menaces related to the use of statins in patients after renal transplantation.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin | 2002 |
[Primary and secondary prevention of coronary disease by statins].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Survival Analysis; Survival Rate; Treatment Outcome | 1999 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Statin-associated memory loss: analysis of 60 case reports and review of the literature.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Memory Disorders; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
Topics: Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2005 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Optimal goals for statin use in patients with coronary artery disease.
Topics: Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Treatment Outcome | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin | 2007 |
Impact of statin dosing intensity on transaminase and creatine kinase.
Topics: Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Transaminases | 2007 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Topics: Animals; Biological Availability; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Nonprescription Drugs; Pharmacogenetics; Pravastatin; Simvastatin | 2008 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk | 2008 |
Biotechnological production and applications of statins.
Topics: Acyltransferases; Anticholesteremic Agents; Aspergillus; Biotechnology; Fermentation; Lovastatin; Pravastatin; Simvastatin | 2010 |
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Diseases; Lipids; Lovastatin; Muscles; Network Meta-Analysis; Patient Safety; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2016 |
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Drug Chronotherapy; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Protein engineering of CYP105s for their industrial uses.
Topics: Actinobacteria; Amino Acid Substitution; Bacterial Proteins; Cholecalciferol; Conserved Sequence; Cytochrome P-450 Enzyme System; Ferredoxins; Gene Expression; Hydroxylation; Isoenzymes; Lovastatin; Molecular Docking Simulation; Mutation; Pravastatin; Protein Engineering; Streptomyces; Substrate Specificity | 2018 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Biotechnological Production of Statins: Metabolic Aspects and Genetic Approaches.
Topics: Animals; Biotechnology; Fermentation; Fungi; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Metabolic Engineering; Pravastatin | 2019 |
Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.
Topics: Atorvastatin; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lovastatin; Network Meta-Analysis; Pravastatin; Proteinuria; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2019 |
78 trial(s) available for pravastatin and lovastatin
| Article | Year |
|---|---|
Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). The European Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1992 |
Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans.
Topics: Administration, Oral; Adult; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Simvastatin | 1992 |
Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance.
Topics: Adolescent; Adult; Arousal; Attention; Cholesterol, LDL; Circadian Rhythm; Double-Blind Method; Humans; Lovastatin; Male; Pravastatin; Psychomotor Performance; Sleep Stages; Wakefulness | 1992 |
Lack of hypotension with lovastatin and pravastatin.
Topics: Adult; Aged; Double-Blind Method; Humans; Hypercholesterolemia; Hypotension, Orthostatic; Lovastatin; Male; Middle Aged; Pravastatin | 1991 |
Effects of lovastatin and pravastatin on sleep efficiency and sleep stages.
Topics: Adult; Female; Humans; Lovastatin; Male; Pravastatin; Sleep; Sleep Stages; Substance Withdrawal Syndrome | 1991 |
Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.
Topics: Adult; Anticholesteremic Agents; Biological Assay; Drug Interactions; Enzyme Inhibitors; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Naphthalenes; Pravastatin; Propranolol; Random Allocation; Reference Values | 1991 |
Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Topics: Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Middle Aged; Pravastatin | 1991 |
Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Biological Transport; Cholesterol; Double-Blind Method; Heptanoic Acids; Humans; Hypercholesterolemia; Kinetics; Lipoproteins, LDL; Lovastatin; Middle Aged; Naphthalenes; Pravastatin | 1990 |
HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Naphthalenes; Phenotype; Pravastatin; Simvastatin; Time Factors | 1990 |
Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.
Topics: Administration, Oral; Adult; Biological Availability; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Naphthalenes; Pravastatin | 1990 |
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Dogs; Double-Blind Method; Drug Evaluation; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipoproteins, HDL; Lipoproteins, VLDL; Lovastatin; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Triglycerides | 1987 |
Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S).
Topics: Adult; Aged; Anticholesteremic Agents; Australia; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Myocardial Ischemia; New Zealand; Pravastatin; Scandinavian and Nordic Countries; Simvastatin; Survival Rate | 1995 |
Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholesterol; Delayed-Action Preparations; Diet; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pravastatin; Receptors, LDL; Simvastatin | 1995 |
Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1995 |
A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients.
Topics: Adult; Anticholesteremic Agents; Double-Blind Method; Ergometry; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Muscles; Permeability; Pravastatin; Prospective Studies; Simvastatin; Statistics as Topic | 1995 |
[Randomized, double-blind comparative study between pravastatin and lovastatin. Evaluation of efficacy and safety].
Topics: Adult; Aged; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin | 1994 |
Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.
Topics: Adult; Affect; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin | 1995 |
Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.
Topics: Adult; Affect; Aged; Cholesterol, LDL; Cognition; Cross-Over Studies; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Polysomnography; Pravastatin; Psychomotor Performance; Sleep | 1994 |
Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Creatinine; Cyclosporine; Follow-Up Studies; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Time Factors; Triglycerides | 1994 |
Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1994 |
[A comparison between lovastatin and pravastatin--effects on lipids, sleep and quality of life in primary hyperlipidemia].
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Hyperlipidemias; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Quality of Life; Sleep | 1994 |
Associations of cholesterol lowering by statins with anger and hostility in hypercholesterolemic men.
Topics: Adult; Aged; Anger; Cholesterol; Double-Blind Method; Hostility; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin | 1994 |
Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Tolerance; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1993 |
Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.
Topics: Adult; Aged; Double-Blind Method; Humans; Hypercholesterolemia; Lipoproteins; Lovastatin; Male; Middle Aged; Polysomnography; Pravastatin; Sleep | 1994 |
Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Brain; Cholesterol; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory, Brain Stem; Female; Humans; Liver; Lovastatin; Male; Pravastatin; Psychomotor Performance; Simvastatin; Sleep; Test Anxiety Scale | 1994 |
Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes.
Topics: Adolescent; Adult; Cholesterol; Erythrocyte Membrane; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Membrane Fluidity; Membrane Lipids; Pravastatin; Simvastatin; Sodium-Potassium-Exchanging ATPase | 1993 |
Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Topics: Adult; Aged; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1993 |
Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Topics: Adult; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Lipids; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Simvastatin | 1993 |
[Comparison of 2 cholesterol synthesis inhibitors (simvastatin and pravastatin)].
Topics: Anticholesteremic Agents; Cholesterol; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1993 |
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group.
Topics: Cholesterol, LDL; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipoproteins; Liver Function Tests; Lovastatin; Male; Middle Aged; Pravastatin; Sleep | 1993 |
Relative safety and efficacy of pravastatin.
Topics: Humans; Hypercholesterolemia; Lovastatin; Pravastatin | 1993 |
Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
Topics: Adult; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Ubiquinone | 1993 |
The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
Topics: Adult; Aged; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Polysomnography; Pravastatin; Simvastatin; Sleep; Sleep Wake Disorders | 1993 |
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Sleep; Treatment Outcome | 1993 |
[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
Topics: Anticholesteremic Agents; Drug Tolerance; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Pravastatin; Simvastatin | 1995 |
Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Double-Blind Method; Humans; Hyperlipidemias; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pravastatin; Time Factors; Triglycerides | 1995 |
Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group.
Topics: Adult; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Quality of Life; Treatment Outcome | 1996 |
[Statin therapy of individuals with high risk for coronary disease].
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Male; Pravastatin; Risk Factors; Scotland; Simvastatin | 1996 |
[A new study on hypercholesterolemia. Statin is effective against heart disease].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Humans; Lovastatin; Male; Middle Aged; Pravastatin; Scandinavian and Nordic Countries; Scotland; Simvastatin | 1996 |
Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Acyl Coenzyme A; Blood Viscosity; Cholesterol; Enzyme Inhibitors; Female; Fibrinogen; Hematocrit; Hemorheology; Humans; Hyperlipoproteinemias; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1996 |
Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1995 |
Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cyclosporine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Male; Metabolic Clearance Rate; Middle Aged; Pravastatin; Triglycerides | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
Topics: Adult; Aged; B-Lymphocytes; Cell Division; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Leukemia, Lymphoid; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Mitogens; Pravastatin; Simvastatin; Thymidine; Tumor Cells, Cultured | 1997 |
[Long term treatment of moderate to severe hypercholesterolemia with low dose statin. Comparison of simvastatin and pravastatin].
Topics: Aged; Anticholesteremic Agents; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Severity of Illness Index; Simvastatin; Time Factors | 1996 |
Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
Topics: Adult; Aged; Antioxidants; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coenzymes; Coronary Disease; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Risk Factors; Ubiquinone | 1997 |
Crossover trial of simvastatin versus pravastatin in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cross-Over Studies; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1997 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Area Under Curve; Cyclosporine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Middle Aged; Pravastatin | 1997 |
Pravastatin and lovastatin in cerebrospinal fluid.
Topics: Anticholesteremic Agents; Humans; Lovastatin; Pravastatin | 1993 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gingival Hyperplasia; Hirsutism; Humans; Hyperlipidemias; Immunosuppressive Agents; Indoles; Kidney Transplantation; Lovastatin; Male; Middle Aged; Pravastatin; Tacrolimus | 1998 |
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Topics: Adolescent; Adult; Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Safety; Simvastatin; Treatment Outcome | 1998 |
The interaction of diltiazem with lovastatin and pravastatin.
Topics: Administration, Oral; Adult; Anticholesteremic Agents; Area Under Curve; Cardiovascular Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Diltiazem; Drug Administration Schedule; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mixed Function Oxygenases; Pravastatin; Reference Values | 1998 |
Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Sleep Wake Disorders; Sleep, REM | 1999 |
Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
Topics: Aged; Alkaline Phosphatase; Anticholesteremic Agents; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Cross-Over Studies; Drug Costs; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; L-Lactate Dehydrogenase; Liver; Lovastatin; Male; Middle Aged; Pravastatin; Triglycerides | 1999 |
Efficacy of three statins at lower maintenance doses.
Topics: Adult; Aged; Anticholesteremic Agents; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1999 |
Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Blood Pressure; Drug Interactions; Enalapril; Female; Heart Rate; Humans; Hypercholesterolemia; Hypertension; Lisinopril; Lovastatin; Male; Middle Aged; Pravastatin | 1999 |
Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lovastatin; Male; Middle Aged; Military Personnel; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk; Risk Factors; Sex Factors; Smoking; Texas; Treatment Outcome | 1999 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Effects of cholestyramine on vitamin E levels in patients treated with statins.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Cholesterol, LDL; Cholestyramine Resin; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Vitamin E | 2000 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Statin therapy and plasma C-reactive protein levels in primary prevention.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin | 2000 |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States | 2001 |
Effects of lovastatin and pravastatin on cognitive function in military aircrew.
Topics: Adult; Anticholesteremic Agents; Cognition; Double-Blind Method; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Military Personnel; Neuropsychological Tests; Pravastatin; Psychomotor Performance | 2001 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Brain; Cholesterol 24-Hydroxylase; Female; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Simvastatin; Steroid Hydroxylases; Treatment Outcome | 2003 |
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Blood Platelets; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pravastatin; Protein Processing, Post-Translational; Simvastatin; Single-Blind Method | 2003 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis.
Topics: Adult; Apoptosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Lymphocytes; Male; Middle Aged; Pravastatin; Pyridines; Simvastatin; Thyroid Gland; Thyroiditis, Autoimmune | 2005 |
Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Topics: Aged; Atorvastatin; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Arthralgia; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Headache; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Patient Dropouts; Pravastatin; Respiratory Tract Infections; Simvastatin; Sinusitis; Treatment Outcome; Triglycerides | 2008 |
Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection.
Topics: Adult; Atorvastatin; Choice Behavior; Decision Support Techniques; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Patient Preference; Pilot Projects; Pravastatin; Precision Medicine; Psychometrics; Rosuvastatin Calcium; Self Efficacy; Simvastatin | 2019 |
321 other study(ies) available for pravastatin and lovastatin
| Article | Year |
|---|---|
Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones.
Topics: Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry, Physical; Cholesterol; Dogs; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Molecular Structure; Pravastatin; Pyrazines; Pyrazoles; Pyridines | 1992 |
Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Topics: Carcinoma, Hepatocellular; Cholesterol; Humans; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.
Topics: Amino Acid Sequence; Animals; Anion Transport Proteins; Base Sequence; Biological Transport; Carrier Proteins; Dehydroepiandrosterone Sulfate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Molecular Sequence Data; Pravastatin; Rats; Taurocholic Acid | 1999 |
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dogs; Estradiol; Fluoresceins; Heptanoic Acids; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Permeability; Pyrroles; Simvastatin; Structure-Activity Relationship | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts.
Topics: Animals; Cell Line; Dehydrocholesterols; Dose-Response Relationship, Drug; Fibroblasts; Homeostasis; Humans; Mice; Molecular Conformation; Neurons; Oxidoreductases Acting on CH-CH Group Donors; Small Molecule Libraries; Sterols; Structure-Activity Relationship | 2016 |
Lovastatin Analogues from the Soil-Derived Fungus Aspergillus sclerotiorum PSU-RSPG178.
Topics: Animals; Aspergillus; Chlorocebus aethiops; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; KB Cells; Lovastatin; Microbial Sensitivity Tests; Molecular Conformation; Mycobacterium scrofulaceum; Nuclear Magnetic Resonance, Biomolecular; Plasmodium falciparum; Soil Microbiology; Thailand; Vero Cells | 2016 |
Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance.
Topics: Humans; Lovastatin; Pravastatin; Psychomotor Performance; Sleep | 1992 |
Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat.
Topics: Animals; Autoradiography; Carbon Radioisotopes; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Organ Specificity; Pravastatin; Rats; Rats, Wistar; Simvastatin; Spleen; Sterols; Testis; Tissue Distribution | 1992 |
Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infusion Pumps, Implantable; Injections, Subcutaneous; Lovastatin; Pravastatin; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Simvastatin | 1992 |
[Diabetes mellitus and hyperlipidemia].
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin; Pravastatin | 1992 |
Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation.
Topics: Animals; Anticholesteremic Agents; Cell Division; Cells, Cultured; Humans; Lovastatin; Myocardium; Pravastatin; Rats; Simvastatin | 1992 |
Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Pravastatin; Time Factors; Triglycerides | 1992 |
Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Cataract; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Pravastatin; Rabbits; Simvastatin | 1992 |
Pravastatin, simvastatin, and lovastatin for lowering serum cholesterol concentrations.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1992 |
Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Desmosterol; Female; Humans; Hyperlipoproteinemia Type II; Isomerism; Lovastatin; Male; Middle Aged; Phytosterols; Pravastatin; Sitosterols; Triglycerides | 1992 |
HMG-CoA reductase inhibitors and sleep.
Topics: Adult; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Sleep; Sleep Stages; Statistics as Topic | 1992 |
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Benzylamines; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Fibrinogen; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Nifedipine; Platelet-Derived Growth Factor; Pravastatin; Simvastatin; Sterols; Swine; Thiophenes | 1992 |
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Topics: Animals; Anticholesteremic Agents; Cyclosporine; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Muscular Diseases; Necrosis; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Structure-Activity Relationship | 1992 |
Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Unsaturated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tissue Distribution | 1992 |
[The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
Topics: Adult; Cataract; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lovastatin; Middle Aged; Pravastatin; Refraction, Ocular; Risk Factors; Simvastatin; Visual Acuity | 1991 |
Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Topics: Anticholesteremic Agents; Chromatography, High Pressure Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Solubility; Structure-Activity Relationship | 1991 |
Pravastatin and simvastatin for hypercholesterolemia.
Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Muscular Diseases; Naphthalenes; Pravastatin; Simvastatin | 1991 |
Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Hypercholesterolemia; Leukocytes; Lovastatin; Middle Aged; Naphthalenes; Pravastatin; Simvastatin | 1991 |
Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.
Topics: Cholesterol, Dietary; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Intestinal Absorption; Lovastatin; Naphthalenes; Pravastatin | 1991 |
Comparison of different HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin; Simvastatin; Triglycerides | 1991 |
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
Topics: Animals; Biliary Tract; Cholestasis; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Microsomes, Liver; Muscular Diseases; Naphthalenes; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin | 1991 |
A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Topics: Cytochrome P-450 Enzyme System; Enzyme Stability; Flavoproteins; Heptanoic Acids; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mixed Function Oxygenases; Models, Biological; NADH, NADPH Oxidoreductases; Naphthalenes; Nucleotides; Oxygenases; Pravastatin; Streptomyces | 1991 |
Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes.
Topics: Animals; Aorta; Cell Division; Cells, Cultured; Depression, Chemical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscle, Smooth, Vascular; Naphthalenes; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Thymidine | 1991 |
Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.
Topics: Adult; Anticholesteremic Agents; Blood-Brain Barrier; Heptanoic Acids; Humans; Lovastatin; Male; Naphthalenes; Pravastatin; Reference Values | 1991 |
Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.
Topics: Acetates; Animals; Cholesterol; Cricetinae; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lens, Crystalline; Liver; Lovastatin; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Time Factors | 1991 |
[HMG-CoA reductase inhibitors].
Topics: Animals; Anticholesteremic Agents; Bile; Cell Division; Cholesterol; Depression, Chemical; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Liver; Lovastatin; Pravastatin | 1991 |
Apolipoprotein(a) and ischaemic heart disease.
Topics: Anticholesteremic Agents; Apolipoproteins A; Coronary Disease; Heptanoic Acids; Humans; Liver; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits.
Topics: Animals; Bile; Cholesterol; Cholesterol, Dietary; Heptanoic Acids; Hypercholesterolemia; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Microsomes, Liver; Naphthalenes; Pravastatin; Rabbits; Receptors, LDL; Simvastatin; Statistics as Topic; Sterol O-Acyltransferase | 1990 |
Lipid lowering drugs.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1990 |
Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Acetates; Acetic Acid; Animals; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileum; Kinetics; L Cells; Lens, Crystalline; Liver; Lovastatin; Male; Mice; Mice, Inbred C57BL; Naphthalenes; Pravastatin; Rats; Simvastatin; Spleen | 1990 |
Formation of dihydroxy derivative of ML-236B from ML-236B (compactin) by lipid peroxidation.
Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Heptanoic Acids; Lipid Peroxidation; Lovastatin; Molecular Structure; Naphthalenes; Pravastatin | 1990 |
Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Binding, Competitive; Brain; Cyclooxygenase Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Naphthalenes; Pravastatin; Rats; Simvastatin | 1990 |
Lovastatin, pravastatin, and serum lipoprotein(a)
Topics: Anticholesteremic Agents; Female; Heptanoic Acids; Humans; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Naphthalenes; Pravastatin | 1990 |
Purification and regulation of mevalonate kinase from rat liver.
Topics: Amino Acids; Animals; Anticholesteremic Agents; Cholestyramine Resin; Chromatography, Affinity; Chromatography, Gel; Chromatography, Ion Exchange; Female; Fluorides; Heptanoic Acids; Homeostasis; Hydroxymethylglutaryl CoA Reductases; Kinetics; Liver; Lovastatin; Molecular Weight; Naphthalenes; Phosphotransferases; Phosphotransferases (Alcohol Group Acceptor); Pravastatin; Rats; Rats, Inbred Strains; Reference Values | 1990 |
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |
Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.
Topics: Adrenal Glands; Animals; Gastric Mucosa; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver; Lovastatin; Male; Naphthalenes; Pravastatin; Rats; Simvastatin; Spleen; Testis; Tissue Distribution | 1989 |
Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus. ML-236B (compactin) induces a cytochrome P-450sca in Streptomyces carbophilus that hydroxylates ML-236B to pravastatin sodium (CS-514), a tissue-selective inhibitor of
Topics: Amino Acids; Cytochrome P-450 Enzyme System; Electrophoresis, Polyacrylamide Gel; Enzyme Induction; Heptanoic Acids; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Naphthalenes; Pravastatin; Spectrophotometry; Streptomyces | 1989 |
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lens, Crystalline; Liver; Lovastatin; Male; Naphthalenes; Organ Specificity; Pravastatin; Rabbits; Rats; Rats, Inbred Strains; Simvastatin; Species Specificity | 1989 |
Statins prevent coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 1995 |
Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.
Topics: Animals; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Mice; Mice, Inbred C57BL; Organ Specificity; Pravastatin; Simvastatin; Spleen; Sterols; Testis | 1995 |
Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Triglycerides | 1993 |
Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Blood Pressure; Carbohydrate Metabolism; Cholesterol; Dogs; Energy Metabolism; Female; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myocardial Stunning; Myocardium; Pravastatin; Simvastatin; Ventricular Function, Left | 1993 |
Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Cost Control; Cost-Benefit Analysis; Health Care Costs; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1994 |
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Cholesterol Esters; Diterpenes; Farnesol; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Macrophages, Peritoneal; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin].
Topics: Aged; Alcoholism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Porphyria Cutanea Tarda; Pravastatin; Simvastatin | 1994 |
Pravastatin versus simvastatin--what happens in the real world?
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Product Surveillance, Postmarketing; Simvastatin | 1995 |
Effect of systemic treatment with cholesterol-lowering drugs on the skin barrier function in humans.
Topics: Adult; Aged; Anticholesteremic Agents; Biological Availability; Cholesterol; Erythema; Female; Galvanic Skin Response; Humans; Hypercholesterolemia; Irritants; Lovastatin; Male; Middle Aged; Patch Tests; Permeability; Pravastatin; Simvastatin; Skin; Sodium Dodecyl Sulfate; Water Loss, Insensible | 1995 |
Replacing lovastatin with pravastatin: effect on serum lipids and costs.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Costs; Drug Utilization; Humans; Lipids; Lovastatin; Pravastatin | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Aorta, Thoracic; Cholesterol; Endothelium, Vascular; Hypercholesterolemia; In Vitro Techniques; Lovastatin; Male; Pravastatin; Rabbits; Simvastatin; Vasodilation | 1994 |
HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
Topics: Drug Combinations; Drug Interactions; Follow-Up Studies; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1995 |
Perspective on cataractogenic potential of HMG-CoA reductase inhibitors.
Topics: Animals; Cataract; Dogs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rabbits; Rats; Simvastatin | 1995 |
In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin.
Topics: Female; Fibroblasts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Pravastatin; Receptors, LDL | 1994 |
Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia.
Topics: Aged; Eosinophils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin E; Leukocyte Count; Lovastatin; Male; Pravastatin; Respiratory Hypersensitivity | 1995 |
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts.
Topics: Adenosine Diphosphate; Animals; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Mitochondria, Heart; Myocardial Ischemia; Oxygen Consumption; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Fluvastatin cost considerations.
Topics: Drug Costs; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1994 |
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in rat liver during ischemia.
Topics: Adenosine Diphosphate; Animals; Cell Fractionation; Glutamic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Liver; Lovastatin; Male; Mitochondria, Liver; Oxygen Consumption; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Succinates | 1994 |
In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Topics: Animals; Anticholesteremic Agents; Blood Proteins; Cells, Cultured; Cholesterol; Drug Stability; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Mevalonic Acid; Muscle, Skeletal; Pravastatin; Pregnancy; Protein Binding; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Chorionic Gonadotropin; Gonadal Steroid Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Testis | 1995 |
Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Anticarcinogenic Agents; Carcinogens; Cholesterol; Colonic Neoplasms; Dimethylhydrazines; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred ICR; Pravastatin; Simvastatin | 1994 |
[Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance].
Topics: Aged; Cholesterol; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1994 |
Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome.
Topics: Administration, Oral; Bezafibrate; Bilirubin; Colestipol; Gilbert Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Liver; Liver Function Tests; Lovastatin; Male; Middle Aged; Pravastatin; Pyrazines; Simvastatin | 1994 |
Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
Topics: Action Potentials; Animals; Electric Stimulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myotonia; Pravastatin; Rabbits; Simvastatin | 1994 |
Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors.
Topics: Animals; Calcium; Cell Survival; Cells, Cultured; Cytosol; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Pravastatin; Rats; Simvastatin | 1994 |
Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors.
Topics: Animals; Cytosol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Liver; Lovastatin; Male; Microsomes, Liver; Phosphatidate Phosphatase; Pravastatin; Rats; Rats, Sprague-Dawley; Triglycerides | 1994 |
[Statin therapy, Q10 and heart failure. Is there any difference between statins?].
Topics: Anticholesteremic Agents; Coenzymes; Heart Failure; Humans; Lovastatin; Pravastatin; Ubiquinone | 1994 |
Enhancement of migration activity in cholesterol-poor endothelial cells by pre-treating with HMG-CoA reductase inhibitors.
Topics: Animals; Blood; Carotid Arteries; Cattle; Cell Movement; Cholesterol; Culture Media; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Lovastatin versus pravastatin for hypercholesterolemia.
Topics: Cholesterol, LDL; Humans; Hypercholesterolemia; Lovastatin; Pravastatin | 1994 |
"A real world" dose comparison of lovastatin and pravastatin.
Topics: Cholesterol; Cholesterol, LDL; Humans; Hypercholesterolemia; Lovastatin; Pravastatin | 1994 |
Effects of lovastatin and pravastatin on coronary artery disease.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic | 1994 |
Lovastatin and myopathy.
Topics: Drug Synergism; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1994 |
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin.
Topics: Anticholesteremic Agents; Cholesterol; Double-Blind Method; Humans; Lovastatin; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
HMG-CoA reductase inhibitor therapy and peripheral neuropathy.
Topics: Female; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Peripheral Nervous System Diseases; Pravastatin | 1994 |
Lovastatin in pravastatin comparative trial: cost-effectiveness.
Topics: Cholesterol, LDL; Cost-Benefit Analysis; Humans; Hypercholesterolemia; Lovastatin; Pravastatin | 1994 |
Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
Topics: Acyclic Monoterpenes; Animals; Aorta; Cell Division; Cells, Cultured; Cholesterol; Diterpenes; Dose-Response Relationship, Drug; Farnesol; Fatty Acids, Monounsaturated; Femoral Artery; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Squalene; Terpenes | 1993 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors.
Topics: Animals; Cholesterol; Crystallography, X-Ray; Heptanoates; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Lovastatin; Microsomes, Liver; Molecular Structure; Pravastatin; Rats | 1993 |
Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.
Topics: Acetates; Acetic Acid; Animals; Biological Transport; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Cattle; Cells, Cultured; Endothelium, Vascular; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Perfusion; Pravastatin; Rats; Rats, Wistar; Sensitivity and Specificity; Simvastatin; Temperature | 1993 |
Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.
Topics: Administration, Oral; Animals; Cholesterol; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lovastatin; Male; Muscles; Muscular Diseases; Pravastatin; Rabbits; Simvastatin; Ubiquinone | 1993 |
Simvastatin, pravastatin and lovastatin: three options for lowering cholesterol.
Topics: Anticholesteremic Agents; Drug Costs; Drug Interactions; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin | 1993 |
Coordinate changes in the low density lipoprotein receptor activity of liver and mononuclear cells in the rabbit.
Topics: Animals; Bile; Cholesterol; Hypolipidemic Agents; Leukocytes, Mononuclear; Lipids; Liver; Lovastatin; Male; Pravastatin; Rabbits; Receptors, LDL; Simvastatin | 1993 |
Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Topics: Anticholesteremic Agents; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Trimethylsilyl Compounds | 1993 |
RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Cholesterol; Cricetinae; Cyclohexanes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Lovastatin; Male; Pravastatin; Rabbits; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured | 1993 |
Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cell Membrane; Cholesterol; Fatty Acids; Humans; Lens Cortex, Crystalline; Lens, Crystalline; Lovastatin; Microsomes; Middle Aged; Organ Culture Techniques; Pravastatin; Simvastatin | 1993 |
Different effects of the hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo.
Topics: Adult; Aged; Animals; Cholesterol; Fatty Acids; Humans; Lens, Crystalline; Lovastatin; Middle Aged; Organ Culture Techniques; Pravastatin; Rats; Rats, Wistar | 1993 |
HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.
Topics: Animals; Carotid Arteries; Cell Division; Cholesterol; Fatty Acids, Monounsaturated; Fluorescent Antibody Technique; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Indoles; Lovastatin; Male; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Reference Values; Simvastatin | 1993 |
Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
Topics: Aging; Animals; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lens, Crystalline; Lovastatin; Microsomes, Liver; Organ Culture Techniques; Pravastatin; Rats; Rats, Wistar; Simvastatin; Time Factors | 1993 |
Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Drug Eruptions; Epidermis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Skin Diseases, Eczematous | 1993 |
Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Topics: Cholesterol; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; RNA, Messenger; Simvastatin; Tumor Cells, Cultured; Up-Regulation | 1993 |
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts.
Topics: Animals; Blood Pressure; Dogs; Enzyme Inhibitors; Female; Hydroxymethylglutaryl CoA Reductases; Lovastatin; Male; Mitochondria, Heart; Myocardial Ischemia; Pravastatin; Simvastatin; Time Factors | 1995 |
Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
Topics: Animals; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Membrane Potentials; Muscle, Skeletal; Pravastatin; Rats; Rats, Wistar; Simvastatin | 1995 |
Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin.
Topics: Aged; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Mitochondria, Muscle; Mitochondrial Myopathies; Pravastatin; Simvastatin | 1995 |
Cost of lipid-lowering statin drugs.
Topics: Anticholesteremic Agents; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
Topics: Animals; Anticholesteremic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Male; Pravastatin; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, LDL; RNA, Messenger; Tricarboxylic Acids | 1996 |
Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mevalonic Acid; Microsomes, Liver; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.
Topics: Animals; Anticholesteremic Agents; Cell Differentiation; Cell Line; Cell Survival; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Molecular Structure; Morphogenesis; Muscle, Skeletal; Myositis; Pravastatin; Stem Cells; Structure-Activity Relationship | 1995 |
Primary prevention of stroke.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Oxidoreductases; Pravastatin; Simvastatin | 1996 |
Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Topics: Animals; Calcium; Cell Differentiation; Cell Division; Cells, Cultured; Cholesterol; Creatine Kinase; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoenzymes; Lovastatin; Mevalonic Acid; Muscle Proteins; Muscle, Skeletal; Phospholipids; Pravastatin; Rats; Rats, Wistar; Simvastatin | 1996 |
Vastatins have a distinct effect on sterol synthesis and progesterone secretion in human granulosa cells in vitro.
Topics: Cells, Cultured; Cholesterol; Culture Media; Enzyme Inhibitors; Female; Follicle Stimulating Hormone; Granulosa Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Luteinizing Hormone; Pravastatin; Progesterone; Simvastatin | 1996 |
Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Male; Middle Aged; Patient Selection; Pravastatin; Retrospective Studies; Treatment Outcome | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Statins and coronary heart disease.
Topics: Anticholesteremic Agents; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
The beneficial effects of HMG-coenzyme A reductase inhibitor in the primary and secondary prevention of atherosclerosis in the coronaries.
Topics: Anticholesteremic Agents; Coronary Artery Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin | 1996 |
Influence on HMG-COA reductase inhibitors on plaque-forming cell (PFC) response in mice.
Topics: Animals; Antibody Formation; Enzyme Inhibitors; Female; Hemolytic Plaque Technique; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred BALB C; Pravastatin; Simvastatin | 1995 |
Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats.
Topics: Animals; Creatine Kinase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscle, Skeletal; Pravastatin; Rats; Rats, Wistar | 1996 |
Effects of systemic treatment with statins on skin barrier function and stratum corneum water-holding capacity.
Topics: Administration, Oral; Adult; Analysis of Variance; Anticholesteremic Agents; Cell Membrane Permeability; Epidermis; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Water Loss, Insensible | 1996 |
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Lovastatin; Microsomes, Liver; Mixed Function Oxygenases; Pravastatin; Simvastatin; Stereoisomerism; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 1996 |
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Topics: Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Time Factors | 1995 |
Improved survival with statin therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Topics: Cyclosporine; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interleukin-2; Killer Cells, Natural; Lovastatin; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocytes; Mevalonic Acid; Phytohemagglutinins; Pravastatin; Simvastatin; Sterols | 1996 |
Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Circadian Rhythm; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Reproducibility of Results; Simvastatin; Xanthomatosis, Cerebrotendinous | 1996 |
Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation.
Topics: Animals; Anticholesteremic Agents; Bromodeoxyuridine; Carotid Arteries; Cell Division; DNA Replication; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorescent Antibody Technique, Indirect; Fluvastatin; Image Processing, Computer-Assisted; Indoles; Infusion Pumps, Implantable; Injections, Intraperitoneal; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Simvastatin | 1995 |
Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Disease; Death, Sudden, Cardiac; Humans; Lovastatin; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Recurrence; Scandinavian and Nordic Countries; Simvastatin; Survival Analysis | 1996 |
Cost effectiveness of lowering cholesterol. Statin treatment should be started early.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
HMG-CoA reductase inhibitor treatment in renal insufficiency.
Topics: Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lovastatin; Pravastatin; Rhabdomyolysis; Simvastatin | 1996 |
Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle.
Topics: Acetic Acid; Adenosine Triphosphate; Anticholesteremic Agents; Cell Division; Cell Survival; Cells, Cultured; DNA; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mitochondria; Muscle, Skeletal; Oxidoreductases; Pravastatin; Simvastatin; Sterols | 1996 |
Beneficial effects of statins. GISSI-Prevenzione Investigators.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Endothelium, Vascular; Humans; Lovastatin; Platelet Aggregation; Pravastatin | 1996 |
Beneficial effects of statins.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Fibrinogen; Humans; Lovastatin; Pravastatin; Serotonin; Simvastatin | 1996 |
Beneficial effects of statins.
Topics: Anticholesteremic Agents; Fibrinogen; Humans; Hypercholesterolemia; Lovastatin; Platelet Aggregation; Pravastatin; Simvastatin | 1996 |
Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model.
Topics: Animals; Anticholesteremic Agents; Cell Division; Cell Survival; DNA; Humans; Lovastatin; Mevalonic Acid; Muscle, Smooth; Pravastatin | 1996 |
[Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells].
Topics: Bone Marrow Cells; Enzyme Inhibitors; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Simvastatin inhibits the division and induces neurite-like outgrowth in PC12 cells.
Topics: Acyl Coenzyme A; Animals; Cell Division; Enzyme Inhibitors; Lovastatin; Mevalonic Acid; Neurites; PC12 Cells; Pravastatin; Rats; Simvastatin | 1996 |
Lipid-lowering for prevention of coronary heart disease: what policy now?
Topics: Adult; Age Factors; Aged; Cholesterol; Coronary Disease; Costs and Cost Analysis; Female; Health Policy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Risk; Simvastatin; United Kingdom | 1996 |
Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia.
Topics: Anesthesia; Animals; Bezafibrate; Calcium; Creatine Kinase; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Pravastatin; Rats; Rats, Wistar; Simvastatin; Urethane | 1997 |
A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Enzyme Inhibitors; Hematopoietic Stem Cells; HL-60 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia, Myeloid; Lovastatin; Pravastatin; Simvastatin | 1997 |
Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Fibrinogen; Follow-Up Studies; Hemorheology; Humans; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Simvastatin | 1996 |
Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Enzyme Inhibitors; Female; Finland; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Morbidity; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland; Simvastatin | 1997 |
Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types.
Topics: Anticholesteremic Agents; Cell Division; Cells, Cultured; Cholesterol; DNA; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; ras Proteins; Simvastatin | 1997 |
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1997 |
Therapy and clinical trials.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Lipids; Lovastatin; Male; Myocardial Infarction; Pravastatin; Simvastatin | 1997 |
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Topics: Analysis of Variance; Animals; Animals, Newborn; Anticholesteremic Agents; Butylamines; Cells, Cultured; Cholesterol; Diterpenes; Enzyme Inhibitors; Farnesol; Farnesyl-Diphosphate Farnesyltransferase; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lovastatin; Mevalonic Acid; Muscle, Skeletal; Pravastatin; Pregnancy; Prodrugs; Protein Biosynthesis; Rats; Rats, Sprague-Dawley; Squalene; Sulfonic Acids | 1997 |
HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Autoradiography; Cells, Cultured; Cholesterol; Densitometry; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isotope Labeling; Lovastatin; Mevalonic Acid; Molecular Weight; Muscle Proteins; Muscle, Skeletal; Polyisoprenyl Phosphates; Pravastatin; Pregnancy; Protein Processing, Post-Translational; Rats; Rats, Sprague-Dawley; Scintillation Counting; Sesquiterpenes; Tritium | 1997 |
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Topics: Animals; Arteriosclerosis; Cell Division; Cholesterol; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Macrophages; Male; Mevalonic Acid; Mice; Mice, Inbred C3H; Oxidation-Reduction; Pravastatin; Simvastatin | 1997 |
[The mechanism of action of hypolipidemic drugs].
Topics: Adipose Tissue; Anticholesteremic Agents; Cholesterol, LDL; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipase; Lipid Peroxidation; Lipoproteins, VLDL; Liver; Lovastatin; Microbodies; Nuclear Proteins; Pravastatin; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Simvastatin; Transcription Factors | 1997 |
Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Animals; Dogs; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipids; Liver; Lovastatin; Male; Pravastatin; Quinolines; Rats; Rats, Wistar; Simvastatin; Sterols | 1997 |
HMG-CoA reductase inhibitors reduce stroke risk, total mortality.
Topics: Cerebrovascular Disorders; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Mortality; Pravastatin; Simvastatin | 1997 |
Aspirin, the poor man's statin?
Topics: Anticoagulants; Aspirin; Female; Humans; Lovastatin; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Risk Factors; Warfarin | 1998 |
Biotransformation of compactin to pravastatin by Actinomadura sp. 2966.
Topics: Actinomycetaceae; Antifungal Agents; Biotransformation; Glucose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin | 1997 |
Molecular approaches for production of pravastatin, a HMG-CoA reductase inhibitor: transcriptional regulation of the cytochrome p450sca gene from Streptomyces carbophilus by ML-236B sodium salt and phenobarbital.
Topics: Amino Acid Sequence; Anticholesteremic Agents; Antifungal Agents; Base Sequence; Cloning, Molecular; Cytochrome P-450 Enzyme System; DNA Mutational Analysis; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Fungal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mixed Function Oxygenases; Molecular Sequence Data; Phenobarbital; Pravastatin; Repressor Proteins; RNA, Messenger; Sequence Analysis, DNA; Streptomyces; Up-Regulation | 1998 |
A retrospective drug utilization evaluation of antihyperlipidaemic agents in a medical centre in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Child; Drug Monitoring; Drug Prescriptions; Drug Utilization; Female; Guidelines as Topic; Humans; Hypercholesterolemia; Insurance, Health; Lovastatin; Male; Middle Aged; Pravastatin; Random Allocation; Retrospective Studies; Taiwan | 1997 |
Do statin drugs lower the risk of stroke?
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Lovastatin; Meta-Analysis as Topic; Pravastatin; Risk Factors; Simvastatin | 1998 |
Lipid-lowering therapy in low-risk patients.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Pravastatin; Risk Factors; Simvastatin | 1998 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
I am 61 years old, and for about six years I've been taking Mevacor for my cholesterol. My doctor is pleased with my results, but I read a newspaper ad that said Pravachol was better. Should I ask for a new prescription?
Topics: Advertising; Anticholesteremic Agents; Humans; Lovastatin; Middle Aged; Pravastatin | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
Topics: Biotransformation; Chromatography, High Pressure Liquid; Cyclosporins; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; In Vitro Techniques; Kinetics; Lovastatin; Male; Microsomes, Liver; Pravastatin | 1999 |
Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
Topics: Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Polymyalgia Rheumatica; Pravastatin; Ventricular Dysfunction, Left | 1999 |
Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
Topics: Cardiovascular Diseases; Cluster Analysis; Costs and Cost Analysis; Databases, Factual; Diagnosis-Related Groups; Female; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Medical Audit; Middle Aged; Pravastatin; Product Surveillance, Postmarketing; Registries; Retrospective Studies; Severity of Illness Index; Simvastatin; United States | 1999 |
Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
Topics: Adolescent; Adult; Creatine Kinase; Dose-Response Relationship, Drug; Exercise; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pain; Pravastatin; Prognosis; Risk Assessment; Simvastatin; Sports | 1999 |
By the way, doctor. I have high cholesterol, and have been taking Mevacor (lovastatin) for two years. Recently, I was switched to Pravachol (pravastatin) because my insurance company would no longer pay for Mevacor. Is it as good?
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center.
Topics: Anticholesteremic Agents; California; Cohort Studies; Cost Savings; Cost-Benefit Analysis; Formularies as Topic; Hospitals, Veterans; Humans; Lipoproteins, LDL; Lovastatin; Outcome Assessment, Health Care; Patient Satisfaction; Pharmacy Service, Hospital; Practice Patterns, Physicians'; Pravastatin; Prospective Studies; Quality of Life; United States | 1999 |
Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Protein Prenylation; Pyrroles; Rats; Simvastatin | 1999 |
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Topics: Angiotensin II; Animals; Animals, Newborn; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; Cell Division; Cell Membrane; Cells, Cultured; DNA; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Myocardium; Naphthalenes; Pravastatin; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; RNA; Simvastatin | 1999 |
Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol; Cholesterol, Dietary; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Organ Size; Pravastatin; Simvastatin; Time Factors; Transaminases; Triglycerides | 1999 |
Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Intestine, Small; Ketoconazole; Lovastatin; Male; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pravastatin; Swine; Troleandomycin | 1999 |
Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Topics: Cell Division; Cells, Cultured; Collagen; DNA; Extracellular Matrix Proteins; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Simvastatin; Thrombospondins; Transcription, Genetic; Transforming Growth Factor beta | 1999 |
Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells.
Topics: Anti-Bacterial Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Cloning, Molecular; Disulfides; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Indole Alkaloids; Lovastatin; Mevalonic Acid; Osteoporosis; Osteosarcoma; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured | 2000 |
Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture.
Topics: Animals; Antigens, Nuclear; Aorta; Apoptosis; Cattle; CDC2-CDC28 Kinases; Cell Division; Cell Survival; Cells, Cultured; Coronary Vessels; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Ki-67 Antigen; Lovastatin; Mevalonic Acid; Mice; Mice, Transgenic; Muscle, Smooth, Vascular; Nuclear Proteins; Pravastatin; Protein Serine-Threonine Kinases; Rats; Retinoblastoma Protein; Simvastatin; Tumor Suppressor Protein p53 | 2000 |
Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
Topics: Administration, Oral; Algorithms; Cholesterol, LDL; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Models, Economic; Pravastatin; Simvastatin; Treatment Outcome | 1999 |
Inhibition of monocyte chemotactic protein-1 synthesis by statins.
Topics: Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Lovastatin; Mevalonic Acid; Monocytes; Pravastatin; RNA, Messenger; Simvastatin | 2000 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Update in women's health.
Topics: Anticholesteremic Agents; Breast Neoplasms; Clinical Trials as Topic; Coronary Artery Disease; Female; Humans; Lovastatin; Pravastatin; Women's Health | 2000 |
A need to redefine the consensus on the use of statins in coronary heart disease prevention.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Humans; Hypercholesterolemia; Lovastatin; Practice Guidelines as Topic; Pravastatin | 2000 |
Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells.
Topics: Analysis of Variance; Anticholesteremic Agents; Dose-Response Relationship, Drug; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Matrix Metalloproteinase 1; Mevalonic Acid; Polyisoprenyl Phosphates; Pravastatin; Sesquiterpenes; Squalene; Time Factors; Tissue Inhibitor of Metalloproteinase-1 | 2000 |
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cardiovascular Diseases; Cholesterol; Cross-Sectional Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prevalence; Retrospective Studies; Risk Factors; Treatment Outcome | 2000 |
Statins: underused by those who would benefit.
Topics: Age Factors; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Humans; Hypolipidemic Agents; Legislation, Drug; Lovastatin; Nonprescription Drugs; Pravastatin; Self Medication; United States | 2000 |
Inhibitory effect of statins on fetal bovine serum-induced proliferation of rat cultured mesangial cells and correlation between their inhibitory effect and transport characteristics.
Topics: Animals; Cattle; Cell Division; Cells, Cultured; Fetal Blood; Glomerular Mesangium; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Male; Pravastatin; Rats; Rats, Sprague-Dawley; Serum Albumin, Bovine; Simvastatin; Temperature | 2000 |
Will statins unseat estrogen?
Topics: Anticholesteremic Agents; Estrogens; Female; Heart Diseases; Hormone Replacement Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Osteoporosis, Postmenopausal; Pravastatin | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Statins as a newly recognized type of immunomodulator.
Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Atorvastatin; Endothelium, Vascular; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Lovastatin; Lymphocyte Activation; Macrophages; Monocytes; Nuclear Proteins; Pravastatin; Pyrroles; Saphenous Vein; T-Lymphocytes; Trans-Activators | 2000 |
[Which statin is more efficient? Concepts and applications in economic evaluation].
Topics: Anticholesteremic Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Simvastatin | 2000 |
Statins & Alzheimer's.
Topics: Aged; Alzheimer Disease; Anticholesteremic Agents; Dementia; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Middle Aged; Pravastatin | 2000 |
Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Cardiomyopathies; Cricetinae; Disease Models, Animal; Female; Lovastatin; Male; Pravastatin; Sex Factors; Survival Analysis; Ubiquinone | 2000 |
Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition.
Topics: Animals; Anticholesteremic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cell Division; Cell Line, Transformed; Cholesterol; Lovastatin; Mevalonic Acid; Neurons; Polyisoprenyl Phosphates; Pravastatin; Protein Prenylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Sesquiterpenes; Squalene; Stem Cells | 2001 |
Is a statin a statin?
Topics: Anticholesteremic Agents; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 2001 |
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.
Topics: Allosteric Site; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Disease Models, Animal; Drug Design; Humans; Integrin alpha4beta1; Integrins; Intercellular Adhesion Molecule-1; Lovastatin; Lymphocyte Activation; Lymphocyte Function-Associated Antigen-1; Macrophage-1 Antigen; Mice; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Naphthalenes; Peritonitis; Pravastatin; Protein Binding; Receptors, Lymphocyte Homing; T-Lymphocytes | 2001 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Statin therapy and the prevention of dementia.
Topics: Alzheimer Disease; Anticholesteremic Agents; Dementia, Vascular; Humans; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic | 2001 |
Chromatographic purification of some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Chromatography, High Pressure Liquid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Spectrophotometry, Ultraviolet | 2001 |
Statins and dementia.
Topics: Anticholesteremic Agents; Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Selection Bias; Simvastatin | 2001 |
FDA panel vetoes OTC version of cholesterol drug.
Topics: Anticholesteremic Agents; Drug Labeling; Humans; Lovastatin; Nonprescription Drugs; Pravastatin; United States; United States Food and Drug Administration | 2000 |
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2001 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins).
Topics: Actins; Blotting, Northern; Cell Line; Connective Tissue Growth Factor; Cytoskeleton; Dose-Response Relationship, Drug; Gene Expression Regulation; Growth Substances; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Lovastatin; Lysophospholipids; Mevalonic Acid; Polyisoprenyl Phosphates; Pravastatin; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; RNA, Messenger; Sesquiterpenes; Simvastatin | 2001 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome | 1999 |
Hyperlipidaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperlipidemias; Lovastatin; Nitric Oxide; Pravastatin; Rabbits; Simvastatin | 2001 |
Transplanted livers and kidneys for HIV+ people.
Topics: Antiretroviral Therapy, Highly Active; Cyclosporine; Hepatitis B; Hepatitis C; HIV Infections; Humans; Hypolipidemic Agents; Kidney Transplantation; Liver Failure; Liver Transplantation; Lovastatin; Pravastatin; Renal Insufficiency; San Francisco | 2001 |
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Dogs; Drug Combinations; Drug Synergism; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Lovastatin; Male; Pravastatin; Simvastatin; Time Factors | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
[Can the action of statins reveal etiology of coronary diseases?].
Topics: Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Humans; Lovastatin; Male; Pravastatin; Randomized Controlled Trials as Topic | 2001 |
Lovastatin increases nitric oxide synthesis in IL-1 beta-stimulated smooth muscle cells.
Topics: Animals; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Sprague-Dawley | 2001 |
Alpha tocopheryl succinate, retinoic acid and polar carotenoids enhanced the growth-inhibitory effect of a cholesterol-lowering drug on immortalized and transformed nerve cells in culture.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Antioxidants; Carotenoids; Cell Line, Transformed; Cells, Cultured; Chromatography, High Pressure Liquid; Lovastatin; Mice; Neurons; Pravastatin; Rats; Tocopherols; Tretinoin; Vitamin E | 2001 |
Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner.
Topics: Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Calcification, Physiologic; Calcium; Cell Line; Core Binding Factor Alpha 1 Subunit; Core Binding Factors; Fatty Acids, Monounsaturated; Fluvastatin; GTPase-Activating Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Indoles; Lovastatin; Mevalonic Acid; Mice; Neoplasm Proteins; Osteoblasts; Osteogenesis; Phosphates; Polyisoprenyl Phosphates; Pravastatin; Protein Prenylation; Sesquiterpenes; Signal Transduction; Transcription Factors; Transforming Growth Factor beta; Tumor Cells, Cultured | 2001 |
Simvastatin and lovastatin, but not pravastatin, interact with MDR1.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Digoxin; Drug Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Swine | 2002 |
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
Topics: Acute Disease; Cholesterol; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Pravastatin; Proportional Hazards Models; Risk Factors; Simvastatin; Substance Withdrawal Syndrome; Survival Rate; Treatment Outcome; Troponin; United States | 2002 |
Statins and risk of polyneuropathy: a case-control study.
Topics: Aged; Case-Control Studies; Causality; Denmark; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Logistic Models; Lovastatin; Male; Middle Aged; Odds Ratio; Polyneuropathies; Pravastatin; Registries; Risk; Risk Assessment; Simvastatin | 2002 |
Inhibition of smooth muscle cell calcium mobilization and aortic ring contraction by lactone vastatins.
Topics: Angiogenesis Inhibitors; Angiotensin II; Animals; Aorta, Thoracic; Calcium; Collagen Type VIII; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Lovastatin; Male; Models, Cardiovascular; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents | 1996 |
Immunosuppressive effects of statins.
Topics: Adjuvants, Immunologic; Cells, Cultured; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interferon-gamma; Lovastatin; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
Topics: ADP Ribose Transferases; Amides; Analysis of Variance; Animals; Botulinum Toxins; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Protein Serine-Threonine Kinases; Pyridines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; RNA, Messenger | 2002 |
Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects.
Topics: Animals; Anticholesteremic Agents; Cell Differentiation; Cell Survival; Culture Media; Cyclic AMP; Cysteine Endopeptidases; Lovastatin; Mevalonic Acid; Multienzyme Complexes; Nerve Degeneration; Neuroblastoma; Neurons; Pravastatin; Proteasome Endopeptidase Complex; Tumor Cells, Cultured | 2002 |
Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac.
Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Blotting, Western; Cardiomegaly; Cells, Cultured; Coloring Agents; Enzyme Activation; Heart; Lovastatin; Mitogen-Activated Protein Kinases; Myocardium; Phenylephrine; Phosphorylation; Pravastatin; Propidium; Rats; Rats, Sprague-Dawley; Tetrazolium Salts; Thiazoles | 2001 |
Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Health Services for the Aged; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Myocardial Infarction; New York; Peripheral Vascular Diseases; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Topics: Animals; Bone Resorption; Calcium; Female; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Osteoclasts; Osteogenesis; Parathyroidectomy; Pravastatin; Protein Prenylation; Pyridines; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin; Thyroidectomy | 2003 |
[Treatment with statins: further data from the Heart Protection Study].
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Female; Humans; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2002 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Safety and statin therapy: reconsidering the risks and benefits.
Topics: Anticholesteremic Agents; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Meta-Analysis as Topic; Muscular Diseases; Pravastatin; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies; Rhabdomyolysis; Transaminases; Treatment Outcome | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
Lovastatin and phospholipase Cgamma regulate constitutive and protein kinase C dependent integrin mediated interactions of human T-cells with collagen.
Topics: Cell Adhesion; Collagen Type IV; Flavonoids; Flow Cytometry; Herpesvirus 2, Saimiriine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin alpha1beta1; Interferon-gamma; Lovastatin; MAP Kinase Kinase 1; Mevalonic Acid; Mitogen-Activated Protein Kinase Kinases; Phospholipase C gamma; Pravastatin; Protein Kinase C; Protein Serine-Threonine Kinases; T-Lymphocytes; Tetradecanoylphorbol Acetate; Type C Phospholipases | 2003 |
Lovastatin induces relaxation and inhibits L-type Ca(2+) current in the rat basilar artery.
Topics: Animals; Anticholesteremic Agents; Basilar Artery; Calcium Channel Blockers; Calcium Channels, L-Type; Female; In Vitro Techniques; Lovastatin; Mevalonic Acid; Muscle Relaxation; Muscle, Smooth, Vascular; Patch-Clamp Techniques; Pilot Projects; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
Current perspectives on statins.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Coronary Artery Disease; Female; Humans; India; Lovastatin; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Differential effects of lipid-lowering agents on human cholinesterases.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Cohort Studies; Dementia; Humans; Hypolipidemic Agents; Lovastatin; Molecular Structure; Pravastatin; Simvastatin | 2004 |
Bioconversion of compactin into pravastatin by Streptomyces sp.
Topics: Bioreactors; Biotransformation; Cell Culture Techniques; Cell Division; Cytochrome P-450 Enzyme System; Lovastatin; Pravastatin; Streptomyces | 2003 |
Toward a role for statins in immunomodulation.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2002 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3beta and transcription factor beta-catenin.
Topics: Animals; Apoptosis; beta Catenin; Caspase 3; Caspases; Cell Hypoxia; Cell Line; Cytoskeletal Proteins; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Lovastatin; Male; Myocardial Infarction; Myocytes, Cardiac; Pravastatin; Rats; Rats, Wistar; Trans-Activators; Ventricular Remodeling | 2004 |
Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex.
Topics: Animals; Blood-Brain Barrier; Brain Chemistry; Cell Division; Cerebral Cortex; Cholesterol; Chromatography, Liquid; Female; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mass Spectrometry; Mice; Mice, Inbred C57BL; Neural Pathways; Oligonucleotide Array Sequence Analysis; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Simvastatin | 2005 |
Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells.
Topics: Antineoplastic Agents; Biomarkers; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Differentiation; Cell Proliferation; Cell Shape; Cell Survival; Cisplatin; Doxorubicin; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mesenchymal Stem Cells; Neuroglia; Phenotype; Polyisoprenyl Phosphates; Pravastatin; Transforming Growth Factor beta | 2004 |
Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain.
Topics: Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Brain Chemistry; Cytokines; Dose-Response Relationship, Drug; Humans; Lovastatin; Male; Mice; Mice, Inbred C3H; Mice, Transgenic; Pravastatin; Protein Processing, Post-Translational | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Lovastatin-induced apoptosis in human melanoma cell lines.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Caspases; Cell Proliferation; Dimethylallyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Melanoma; Mice; Polyisoprenyl Phosphates; Pravastatin; Sesquiterpenes | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells.
Topics: Atorvastatin; Cell Proliferation; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Mitogens; Pravastatin; Pyrroles; Simvastatin | 2005 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
[Hypolipidemic treatment under special conditions: posttransplant and/or immunosuppressive therapy].
Topics: Cyclosporine; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2005 |
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
Topics: Animals; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Pravastatin; Pyrroles; Serotonin; Simvastatin; Swine; Time Factors; Vasoconstriction | 2006 |
Statin wars following coronary revascularization--evidence-based clinical practice?
Topics: Aged; Drug Prescriptions; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Myocardial Ischemia; Myocardial Revascularization; Outpatients; Postoperative Care; Pravastatin; Retrospective Studies; Secondary Prevention; Simvastatin; Treatment Outcome | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Screening of compactin-resistant microorganisms capable of converting compactin to pravastatin.
Topics: Bacteria; Chromatography, High Pressure Liquid; Culture Media; Hydroxylation; Lovastatin; Microbial Sensitivity Tests; Pravastatin | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Fatty Acids, Monounsaturated; Fluvastatin; G1 Phase; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; p21-Activated Kinases; Phosphorylation; Pravastatin; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Simvastatin | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Topics: Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blotting, Western; Cell Line; Cell Proliferation; Cell Survival; Constitutive Androstane Receptor; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Endothelial Cells; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Glucocorticoid; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saphenous Vein; Transcription Factors; Up-Regulation | 2007 |
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Brain; Heptanoic Acids; Lactones; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Pravastatin; Pyrroles; Simvastatin | 2007 |
HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells.
Topics: Atherosclerosis; Cell Adhesion; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelial Cells; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intercellular Adhesion Molecule-1; Leukocytes; Lovastatin; NF-kappa B; Nicotine; Nicotinic Agonists; Pravastatin; Protein Kinase C; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction; Simvastatin; Smoking; Superoxide Dismutase; Time Factors; Vascular Cell Adhesion Molecule-1 | 2007 |
On the factors modulating the effect of statins on malignant cell proliferation.
Topics: Annexin A5; Atorvastatin; Cell Division; Cell Line, Tumor; DNA Fragmentation; DNA, Neoplasm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; K562 Cells; Kinetics; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 2007 |
Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromans; Dose-Response Relationship, Drug; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mammary Neoplasms, Animal; MAP Kinase Kinase 4; Mice; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pravastatin; Proto-Oncogene Proteins c-akt; Simvastatin; Vitamin E | 2007 |
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro.
Topics: Adult; Apoptosis; Atorvastatin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Middle Aged; Phagocytes; Phagocytosis; Pravastatin; Pyrroles; Simvastatin | 2008 |
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
Topics: Adult; Animals; Atorvastatin; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; T-Lymphocytes, Regulatory; Up-Regulation | 2008 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin | 2007 |
The association between statins and cancer incidence in a veterans population.
Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pravastatin; Proportional Hazards Models; Research Design; Retrospective Studies; Simvastatin; United States; Veterans | 2008 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
The Food and Drug Administration and over-the-counter statins: an opportunity lost?
Topics: Adult; Aged; Cardiovascular Diseases; Contraindications; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Nonprescription Drugs; Pravastatin; Pregnancy; Self Administration; United States; United States Food and Drug Administration | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Apoptosis; Barrett Esophagus; Caspase 3; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Esophageal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Lovastatin; Mevalonic Acid; Nitrobenzenes; Polyisoprenyl Phosphates; Pravastatin; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sesquiterpenes; Signal Transduction; Simvastatin; Sulfonamides | 2008 |
Statins in esophageal cancer cell lines: promising lead?
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Cell Line, Tumor; Dose-Response Relationship, Drug; Esophageal Neoplasms; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Lovastatin, but not pravastatin, limits in vitro infection due to Coxiella burnetii.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Coxiella burnetii; Lovastatin; Mice; Microbial Sensitivity Tests; Pravastatin | 2008 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Statins limit Rickettsia conorii infection in cells.
Topics: Algorithms; Animals; Anticholesteremic Agents; Culture Media; Image Processing, Computer-Assisted; L Cells; Lovastatin; Mice; Microbial Sensitivity Tests; Pravastatin; Rickettsia conorii | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells.
Topics: Cardiovascular Diseases; Cell Line; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Serum Albumin; Simvastatin | 2009 |
Efficient biotransformations using Escherichia coli with tolC acrAB mutations expressing cytochrome P450 genes.
Topics: Bacterial Outer Membrane Proteins; Calcifediol; Cholecalciferol; Cholestenones; Cytochrome P-450 Enzyme System; Escherichia coli; Escherichia coli Proteins; Hydrophobic and Hydrophilic Interactions; Intracellular Space; Lovastatin; Membrane Transport Proteins; Mutation; Oxidation-Reduction; Pravastatin; Spectrum Analysis; Stereoisomerism; Substrate Specificity | 2009 |
Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelium; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Mevalonic Acid; Ovarian Neoplasms; Polyisoprenyl Phosphates; Pravastatin; Sesquiterpenes; Signal Transduction; Simvastatin; Uterine Cervical Neoplasms; Water | 2010 |
Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions.
Topics: Antibodies, Monoclonal; Apoptosis; Cell Adhesion; Cell Shape; Cell Survival; Dose-Response Relationship, Drug; Eosinophils; Fatty Acids, Monounsaturated; Fluvastatin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intercellular Adhesion Molecule-1; Lovastatin; Macrophage-1 Antigen; Mevalonic Acid; Microfluidic Analytical Techniques; Microfluidics; Pravastatin; Recombinant Proteins; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2009 |
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Genotype; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2009 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |
Effects of fungal statins on high-glucose-induced mouse mesangial cell hypocontractility may involve filamentous actin, t-complex polypeptide 1 subunit beta, and glucose regulated protein 78.
Topics: Actins; Acyl Coenzyme A; Animals; Cell Division; Endoplasmic Reticulum Chaperone BiP; Glomerular Mesangium; Glucose; Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Lovastatin; Mice; Pravastatin; Simvastatin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetradecanoylphorbol Acetate | 2010 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Construction of a novel expression vector in Pseudonocardia autotrophica and its application to efficient biotransformation of compactin to pravastatin, a specific HMG-CoA reductase inhibitor.
Topics: Acetone; Base Sequence; Biotransformation; Cloning, Molecular; Cytochrome P-450 Enzyme System; Gene Expression; Genetic Engineering; Genetic Vectors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Industrial Microbiology; Lovastatin; Molecular Sequence Data; Plasmids; Pravastatin; Promoter Regions, Genetic; Replication Origin; Streptomyces | 2011 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
[Retention behavior of statins in microemulsion liquid chromatography].
Topics: Atorvastatin; Chromatography, Liquid; Emulsions; Heptanoic Acids; Lovastatin; Models, Chemical; Pravastatin; Pyrroles; Simvastatin | 2011 |
Efficient bioconversion of compactin to pravastatin by the quinoline-degrading microorganism Pseudonocardia carboxydivorans isolated from petroleum-contaminated soil.
Topics: Actinomycetales; Base Sequence; Biodegradation, Environmental; Culture Media; DNA, Ribosomal; Lovastatin; Molecular Sequence Data; Petroleum Pollution; Phylogeny; Pravastatin; Quinolines; Soil Microbiology | 2011 |
In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ascorbic Acid; Cimetidine; Erythrocytes; Famotidine; Hemolysis; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Lovastatin; Nizatidine; Omeprazole; Pantoprazole; Pravastatin; Proton Pump Inhibitors; Ranitidine; Ultraviolet Rays | 2012 |
HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model.
Topics: Animals; Cicatrix, Hypertrophic; Disease Models, Animal; Ear; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rabbits; Simvastatin; Wound Healing | 2012 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Development and validation of a simple and fast HPLC method for determination of lovastatin, pravastatin and simvastatin.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lovastatin; Naphthalenes; Pravastatin; Reproducibility of Results; Sensitivity and Specificity; Simvastatin | 2012 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
Engineering of a hybrid biotransformation system for cytochrome P450sca-2 in Escherichia coli.
Topics: Biodegradation, Environmental; Bioengineering; Circular Dichroism; Cytochrome P-450 Enzyme System; Escherichia coli; Ferredoxins; Hydroxylation; Industrial Microbiology; Lovastatin; Models, Molecular; NADH, NADPH Oxidoreductases; Oxidation-Reduction; Pravastatin; Pseudomonas putida; Recombinant Proteins | 2013 |
Anti-atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells.
Topics: Acyl Coenzyme A; Angiopoietin-2; Atherosclerosis; Cell Survival; Cells, Cultured; Endothelial Cells; Exocytosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Simvastatin; Weibel-Palade Bodies | 2013 |
Evaluation of a method using high performance liquid chromatography with ultraviolet detection for the determination of statins in macromycetes of the genus Pleurotus cultivated by fermentation processes.
Topics: Agriculture; Chromatography, High Pressure Liquid; Drug Stability; Fermentation; Limit of Detection; Lovastatin; Pleurotus; Pravastatin; Simvastatin; Waste Products | 2013 |
Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Female; Gonadal Steroid Hormones; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Networks and Pathways; Ovary; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Theca Cells | 2014 |
HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K(+)-channel currents in murine thymocytes.
Topics: Animals; Cell Membrane; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kv1.3 Potassium Channel; Lovastatin; Male; Mice, Inbred Strains; Pravastatin; Simvastatin; Thymocytes | 2014 |
Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genetic Association Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver-Specific Organic Anion Transporter 1; Lovastatin; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Risk Assessment; Simvastatin | 2015 |
Statins inhibit blastocyst formation by preventing geranylgeranylation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Benzamides; Blastocyst; Cell Cycle Proteins; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mevalonic Acid; Mice; Phosphoproteins; Polyisoprenyl Phosphates; Pravastatin; Prenylation; Quinuclidines; Sesquiterpenes; YAP-Signaling Proteins | 2016 |
Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Topics: Aged; Aged, 80 and over; Atorvastatin; Clinical Trials as Topic; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Knowledge, Attitudes, Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Interrupted Time Series Analysis; Lovastatin; Male; Nova Scotia; Pravastatin; Prescription Drugs; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2016 |
Identification of a new plasmid-encoded cytochrome P450 CYP107DY1 from Bacillus megaterium with a catalytic activity towards mevastatin.
Topics: Bacillus megaterium; Biotransformation; Cytochrome P-450 Enzyme System; Escherichia coli; Hydroxylation; Lovastatin; Plasmids; Pravastatin; Substrate Specificity | 2016 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells.
Topics: Atorvastatin; Cells, Cultured; Humans; Lovastatin; PCSK9 Inhibitors; Pravastatin; Proprotein Convertase 9; Receptors, LDL; Structure-Activity Relationship | 2017 |
Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study.
Topics: Adult; Aged; Atorvastatin; Depression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Propensity Score; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Suicide, Attempted; United States | 2018 |
Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Amides; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cyclohexenes; Cytokines; Diphosphonates; Fibroblasts; Fluvastatin; Gene Expression Regulation; Heart; Heart Diseases; Humans; Interleukin-33; Lovastatin; Mevalonic Acid; Monoterpenes; Myocardium; Myocytes, Cardiac; Pravastatin; Pyridines; rhoA GTP-Binding Protein; Simvastatin; Thiazolidines | 2018 |
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells.
Topics: Atorvastatin; Cell Line; Cell Movement; Cell Proliferation; Endometriosis; Endometrium; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin; Stromal Cells | 2019 |
Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy.
Topics: Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Bilayers; Lovastatin; Magnetic Resonance Spectroscopy; Phosphatidylcholines; Phospholipids; Pravastatin; Simvastatin | 2019 |
Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring.
Topics: Atorvastatin; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Drug Monitoring; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Lovastatin; Medication Adherence; Pravastatin; Quality Control; Reference Standards; Tandem Mass Spectrometry | 2020 |
Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.
Topics: Animals; Atorvastatin; Caspase 3; Caspase 7; Cell Line; Cell Survival; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Myoblasts; Pravastatin; Protective Agents; Rats; Resveratrol; Signal Transduction; Simvastatin | 2020 |
Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Topics: A549 Cells; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Lung Neoplasms; Pravastatin; Rosuvastatin Calcium; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2021 |
In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.
Topics: Animals; Biosynthetic Pathways; Cell Line, Tumor; Chemical and Drug Induced Liver Injury; Diterpenes; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred NOD; Mice, SCID; Pravastatin; Protein Prenylation; Terpenes; Triazoles; Xenograft Model Antitumor Assays | 2021 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |